<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Drugs R D</journal-id><journal-id journal-id-type="iso-abbrev">Drugs R D</journal-id><journal-title-group><journal-title>Drugs in R&#x00026;D</journal-title></journal-title-group><issn pub-type="ppub">1174-5886</issn><issn pub-type="epub">1179-6901</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5629135</article-id><article-id pub-id-type="publisher-id">195</article-id><article-id pub-id-type="doi">10.1007/s40268-017-0195-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dagenais</surname><given-names>Ren&#x000e9;e</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wilby</surname><given-names>Kyle John</given-names></name><address><phone>+974 4403 5606</phone><email>kjw@qu.edu.qa</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Elewa</surname><given-names>Hazem</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ensom</surname><given-names>Mary H. H.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution>Faculty of Pharmaceutical Sciences, Pharmaceutical Sciences Building, </institution><institution>University of British Columbia, </institution></institution-wrap>Vancouver, BC Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0634 1084</institution-id><institution-id institution-id-type="GRID">grid.412603.2</institution-id><institution>College of Pharmacy, </institution><institution>Qatar University, </institution></institution-wrap>PO Box 2713, Doha, Qatar </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.413941.a</institution-id><institution>Department of Pharmacy, </institution><institution>Children&#x02019;s and Women&#x02019;s Health Centre of British Columbia, </institution></institution-wrap>Vancouver, BC Canada </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2017</year></pub-date><volume>17</volume><issue>3</issue><fpage>341</fpage><lpage>361</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Genetic polymorphisms are known to influence outcomes with phenytoin yet effects in the Middle East and North Africa region are poorly understood.</p></sec><sec><title>Objectives</title><p id="Par2">The objective of this systematic review was to evaluate the impact of genetic polymorphisms on phenytoin pharmacokinetics and clinical outcomes in populations originating from the Middle East and North Africa region, and to characterize genotypic and allelic frequencies within the region for genetic polymorphisms assessed.</p></sec><sec><title>Methods</title><p id="Par3">MEDLINE (1946&#x02013;3 May, 2017), EMBASE (1974&#x02013;3 May, 2017), Pharmacogenomics Knowledge Base, and Public Health Genomics Knowledge Base online databases were searched. Studies were included if genotyping and analyses of phenytoin pharmacokinetics were performed in patients of the Middle East and North Africa region. Study quality was assessed using a National Institutes of Health assessment tool. A secondary search identified studies reporting genotypic and allelic frequencies of assessed genetic polymorphisms within the Middle East and North Africa region.</p></sec><sec><title>Results</title><p id="Par4">Five studies met the inclusion criteria. <italic>CYP2C9</italic>, <italic>CYP2C19</italic>, and multidrug resistance protein 1 C3435T variants were evaluated. While <italic>CYP2C9*2</italic> and <italic>*3</italic> variants significantly reduced phenytoin metabolism, the impacts of <italic>CYP2C19*2</italic> and <italic>*3</italic> variants were unclear. The multidrug resistance protein 1 CC genotype was associated with drug-resistant epilepsy, but reported impacts on phenytoin pharmacokinetics were conflicting. Appreciable variability in minor allele frequencies existed both between and within countries of the Middle East and North Africa region.</p></sec><sec><title>Conclusions</title><p id="Par5">
<italic>CYP2C9</italic>&#x000a0;decrease-of-function alleles altered phenytoin pharmacokinetics in patients originating from the Middle East and North Africa region. The impacts of <italic>CYP2C19</italic> and multidrug resistance protein 1 C3435T variants on phenytoin pharmacokinetic and clinical outcomes are unclear and require further investigation. Future research should focus on the clinical outcomes associated with phenytoin therapy.</p><p id="Par6">PROSPERO 2017: CRD42017057850</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing AG 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar1"><title>Key Points</title><p id="Par7">
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">In patients originating from the Middle East and North Africa region, phenytoin metabolism was significantly decreased by genetic polymorphisms of the cytochrome P450 (CYP) 2C9 enzyme; the impacts of <italic>CYP2C19</italic> and multidrug resistance protein 1 C3435T polymorphisms were unclear.</td></tr><tr><td align="left">The impacts of genetic polymorphisms on clinical outcomes associated with phenytoin are not well described in the literature and warrant further investigation.</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par8">Since the discovery of its anticonvulsant properties in 1938 [<xref ref-type="bibr" rid="CR1">1</xref>], phenytoin has been widely used for both the acute management and chronic prevention of seizures [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Its primary mechanism in treating and preventing seizures is through preferential binding to inactivated sodium channels, which inhibits neuronal generation of sustained high-frequency bursts of action potentials [<xref ref-type="bibr" rid="CR4">4</xref>]. Phenytoin has a narrow therapeutic index, with 40&#x02013;80&#x000a0;&#x000b5;mol/L (10&#x02013;20&#x000a0;mg/L) being the recommend therapeutic range; however, this is often difficult to achieve due to wide interpatient variability in dose response and concentrations achieved from a given dose, as well as the capacity-limited metabolism of phenytoin [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par9">Factors such as patient body size and composition, serum albumin levels, comorbid disease states, and drug&#x02013;drug interactions have been shown to contribute to the interpatient variability of the effect of phenytoin. Additionally, genetic polymorphisms of enzymes and transporters targeting phenytoin pharmacokinetics have been recognized as a significant contributor to the exhibited interpatient variability [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Evidence linking the cytochrome P450 (CYP) 2C9 polymorphism to the concentration of phenytoin has led to the development of guidelines tailoring the initial dose of phenytoin based on the <italic>CYP2C9</italic> genotype [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Though not as well studied, there is evidence to suggest that polymorphisms of <italic>CYP2C19</italic> may also significantly impact the concentration of phenytoin and warrant dosage adjustments [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Additional enzymes and drug transporters have been investigated, but the implications of these polymorphisms are not well established [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par10">Cited studies investigating the impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of phenytoin have predominantly been conducted in patients of European, Indian, and East Asian origin; however, few studies have been conducted in patients originating from the Middle East and North Africa (MENA) region [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. As a result of migration and significant admixture of European, Asian, and African populations dating back over thousands of years, the MENA region has a unique genetic diversity, with great variability in minor allelic frequencies (MAF) of genetic polymorphisms [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Even within the MENA region itself, there is great diversity. For example, while populations of Arabic and Iranian origin have both European and African ancestry, those of Iranian origin also have a significant level of Asian admixture [<xref ref-type="bibr" rid="CR15">15</xref>]. Furthermore, as a result of consanguinity, some countries within the MENA region may exhibit relatively less genetic diversity [<xref ref-type="bibr" rid="CR15">15</xref>]. Therefore, results of previous studies conducted in patients of different ethnic origins are not readily generalizable, and a focused review of the literature addressing genetic polymorphisms and the associated implications regarding phenytoin in individuals originating from the MENA region is warranted.</p><p id="Par11">The primary objective of this systematic review was to evaluate the impact of genetic polymorphisms on phenytoin pharmacokinetics, specifically in populations originating from the MENA region. Secondary objectives were to evaluate the impact of genetic polymorphisms on clinical outcomes associated with phenytoin therapy, as well as to characterize the genotypic and allelic frequencies of each polymorphism identified in the primary search within the MENA region.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Search Strategy</title><p id="Par12">A comprehensive search of the MEDLINE (1946&#x02013;May 2017), EMBASE (1974&#x02013;May 2017), Pharmacogenomics Knowledge Base (PharmGKB), and Public Health Genomics Knowledge Base (PHGKB) online databases was conducted to identify existing literature addressing the primary research question. An example of the search terms and Boolean connectors used in MEDLINE is outlined in the Appendix, and is reflective of the search strategy used in EMBASE. References of pertinent studies were also searched manually to identify additional studies not identified in the electronic search. For each polymorphism assessed in the studies that met the inclusion criteria, a secondary search was conducted to identify the reported variant MAF, specifically within the MENA region.</p></sec><sec id="Sec4"><title>Selection of Studies</title><p id="Par13">Studies were eligible for inclusion if participants originated from the MENA region, received at least one dose of phenytoin with a subsequent pharmacokinetic analysis, and were genotyped for a polymorphism that may impact phenytoin pharmacokinetics. Although understanding the impact of genetic polymorphisms on clinical outcomes associated with phenytoin therapy was a secondary objective of this review, eligible studies were not required to report on clinical outcomes. Two reviewers (RD, KW) screened potentially relevant studies by title and abstract, and then by full text to exclude any studies that did not fulfill the inclusion criteria. For the review regarding variant MAF, studies were included if participants originated from the MENA region and&#x000a0;were genotyped for one or more of the polymorphisms assessed in the primary review.</p></sec><sec id="Sec5"><title>Data Extraction and Management</title><p id="Par14">Data from each included study were extracted and tabulated. Extracted data included: author, year of publication, study population (country of origin, practice setting, inclusion and exclusion criteria), sample size, study design, genetic polymorphism(s) assessed, phenytoin dosing, assay methods for phenytoin serum concentrations and genotyping, MAF of the genetic polymorphism(s), as well as final study results. For studies also including participants from outside of the MENA region, only data regarding participants who originated from the MENA region were extracted.</p><p id="Par15">Similarly, for studies included in the review of variant MAF, the following data were extracted: author, country of origin, sample size, genetic polymorphism(s) assessed, as well as the computed genotypic and allelic frequencies. If studies eligible for inclusion also reported data from participants originating outside of the MENA region, only data on participants who originated from the MENA region were extracted.</p></sec><sec id="Sec6"><title>Quality Assessment</title><p id="Par16">The quality of each study included in the primary review was assessed by two reviewers (RD, KW) using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, from the National Institutes of Health, National Heart, Lung, and Blood Institute [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec7"><title>Data Synthesis</title><p id="Par17">Data extracted from the included studies were assessed descriptively. If two or more studies reported the genotypic or allelic frequency of a given polymorphism, data from all studies were reported. The highest and lowest frequencies extracted for each polymorphism were assessed to estimate variants&#x02019; MAF range within the MENA region.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Study Selection</title><p id="Par18">A total of five studies fulfilled the inclusion criteria for this review, as depicted in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Of the 30 articles screened for eligibility, ten were excluded for subjects not originating from the MENA region [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>], seven were excluded for phenytoin concentrations not being assessed [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>], five were excluded for both subjects not originating from the MENA region and phenytoin concentrations not being assessed [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>], one was excluded for genetic polymorphisms not being assessed [<xref ref-type="bibr" rid="CR39">39</xref>], and two were excluded for being poster abstracts [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Between the five included studies<italic>, CYP2C9*1, *2,</italic> and <italic>*3; CYP2C19*1, *2,</italic> and <italic>*3;</italic> and multidrug resistance protein 1 [<italic>MDR1</italic>, also known as ATP-binding cassette sub-family B member 1 (ABCB1)] C3435T polymorphisms were evaluated. The study population, phenytoin regimen, and genetic polymorphism(s) assessed varied between studies; summaries of each study are provided in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow chart of included studies [<xref ref-type="bibr" rid="CR146">146</xref>]. <italic>MENA</italic> Middle East and North Africa, <italic>PHT</italic> phenytoin</p></caption><graphic xlink:href="40268_2017_195_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Summary of studies assessing the impact of genetic polymorphisms on phenytoin pharmacokinetics and/or clinical outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study, year</th><th align="left">Country/study population</th><th align="left">PHT dosing regimen</th><th align="left">Genotype(s)/reported allelic frequencies percentage</th><th align="left" colspan="5">Pharmacokinetic outcomes</th></tr></thead><tbody><tr><td align="left" rowspan="4">Aynacioglu et al. [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left" rowspan="4">Turkey<break/>&#x000a0;Outpatients (<italic>n</italic> = 280); healthy volunteers (<italic>n</italic> = 218)<break/>&#x000a0;&#x000a0;PHT PK analysis in healthy volunteer subgroup (<italic>n</italic> = 101)</td><td align="left" rowspan="4">300 mg PO &#x000d7; 1<break/>&#x000a0;Sample collected 12-h post-dose</td><td align="left" rowspan="4">
<italic>CYP2C9</italic>
<break/>&#x000a0;Study population<break/>&#x000a0;&#x000a0;*1 = 79.4<break/>&#x000a0;&#x000a0;*2 = 10.6<break/>&#x000a0;&#x000a0;*3 = 10<break/>&#x000a0;Population included in PHT PK analysis:<break/>&#x000a0;&#x000a0;*1 = 81.7<break/>&#x000a0;&#x000a0;*2 = 9.4<break/>&#x000a0;&#x000a0;*3 = 8.9</td><td align="left" colspan="2">Genotype</td><td align="left" colspan="3">Serum PHT, mean mg/L (95% CI)</td></tr><tr><td align="left" colspan="2">CYP2C9*1/*1<break/>CYP2C9*1/*2<break/>CYP2C9*1/*3<break/>CYP2C9*2/*2<break/>CYP2C9*2/*3<break/>CYP2C9*3/*3</td><td align="left" colspan="3">4.16 (3.86&#x02013;4.46)<break/>5.52 (4.66&#x02013;6.39)<break/>5.65 (4.86&#x02013;6.43)<break/>6.58 (1.64&#x02013;11.51)<break/>Not observed<break/>5.92<sup>a</sup>
</td></tr><tr><td align="left" colspan="2">Genotype</td><td align="left" colspan="3">p-HPPH/PHT ratio (95% CI)</td></tr><tr><td align="left" colspan="2">CYP2C9*1/*1<break/>CYP2C9*1/*2<break/>CYP2C9*1/*3<break/>CYP2C9*2/*2<break/>CYP2C9*2/*3<break/>CYP2C9*3/*3</td><td align="left" colspan="3">0.43 (0.39&#x02013;0.47)<break/>0.26 (0.21&#x02013;0.31)<break/>0.21 (0.18&#x02013;0.24)<break/>0.14 (0.13&#x02013;0.14)<break/>Not observed<break/>0.02<sup>a</sup>
</td></tr><tr><td align="left" rowspan="3">Kerb et al. [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left" rowspan="3">Turkey<break/>&#x000a0;Healthy volunteers (<italic>n</italic>&#x000a0;=&#x000a0;96)</td><td align="left" rowspan="3">300 mg PO &#x000d7; 1<break/>&#x000a0;Sample collected 12-h post-dose</td><td align="left" rowspan="3">
<italic>CYP2C9</italic>
<break/>&#x000a0;*1 = 81.3<break/>&#x000a0;*2 = 10.1<break/>&#x000a0;*3 = 8.8<break/>
<italic>CYP2C19</italic>
<break/>&#x000a0;*1 = 88.3<break/>&#x000a0;*2 = 11.7<break/>
<italic>MDR1 (ABCB1) C3435T</italic>
<break/>&#x000a0;C = 52.6<break/>&#x000a0;T = 47.4</td><td align="left" colspan="2">Genotype</td><td align="left" colspan="3">Serum PHT, mean mg/L &#x000b1; SD</td></tr><tr><td align="left" colspan="2">CYP2C9*1/*1<break/>CYP2C9*1/*2<break/>CYP2C9*1/*3<break/>CYP2C9*2/*2<break/>CYP2C9*2/*3<break/>CYP2C9*3/*3<break/>CYP2C19*1/*1<break/>CYP2C19*1/*2<break/>CYP2C91*2/*2<break/>MDR1 CC<break/>MDR1 CT<break/>MDR1 TT</td><td align="left" colspan="3">4.20 &#x000b1; 1.25<break/>5.52 &#x000b1; 1.43<break/>5.54 &#x000b1; 1.47<break/>6.58 &#x000b1; 1.99<break/>Not observed<break/>5.92<sup>a</sup>
<break/>4.73 &#x000b1; 1.47<break/>4.49 &#x000b1; 1.68<break/>4.40 &#x000b1; 1.41<break/>4.27 &#x000b1; 1.74<break/>4.85 &#x000b1; 1.33<break/>4.87 &#x000b1; 1.36</td></tr><tr><td align="left" colspan="5">Multiple linear regression indicates the number of polymorphic <italic>CYP2C9</italic> alleles and <italic>MDR1*T</italic> alleles account for 14.1 and 1.3% of the variability in phenytoin serum concentrations, respectively (<italic>r</italic>
<sup>2</sup> = 0.154, <italic>p</italic> = 0.0002)</td></tr><tr><td align="left" rowspan="3">Ozkaynakci et al. [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left" rowspan="3">Turkey<break/>&#x000a0;Epilepsy clinic outpatients taking PHT mono- or polytherapy (<italic>n</italic> = 101)<break/>&#x000a0;&#x000a0;Seizure etiology: epilepsy, brain tumor, glioma, head trauma, or AVM<break/>&#x000a0;&#x000a0;Polytherapy, mostly CBZ, LTG, or VPA</td><td align="left" rowspan="3">Mean dose &#x000a0;4.1&#x000a0;mg/kg/day PO<break/>Mean duration<break/>&#x000a0;96.6&#x000a0;weeks (&#x02265;7&#x000a0;days)<break/>
<italic>C</italic>
<sub>tr</sub> collected pre-dose</td><td align="left" rowspan="3">
<italic>CYP2C9</italic>
<break/>&#x000a0;*1 = 89.2<break/>&#x000a0;*2 = 7.4<break/>&#x000a0;*3 = 3.4<break/>
<italic>CYP2C19</italic>
<break/>&#x000a0;*1 = 70.1<break/>&#x000a0;*2 = 19.6<break/>&#x000a0;*3 = 10.3</td><td align="left" colspan="2">Genotype group (CYP2C9, 2C19)</td><td align="left" colspan="3">Serum PHT <italic>C</italic>
<sub>tr</sub>, mean mg/L (SEM)</td></tr><tr><td align="left" colspan="2">*1/*1, *1/*1<break/>*1/*1, *1/*2<break/>*1/*1, *1/*3<break/>*1/*1, *2/*2<break/>*1/*1, *2/*3<break/>*1/*2, *1/*1<break/>*1/*2, *1/*2<break/>*1/*2, *1/*3<break/>*1/*3, *1/*1<break/>*1/*3, *1/*3<break/>*1/*3, *2/*3<sup>*</sup>
</td><td align="left" colspan="3">7.43 (0.73)<sup>&#x02020;</sup>
<break/>9.16 (1.46)<sup>***</sup>
<break/>7.51 (2.56)<sup>***</sup>
<break/>9.80 (4.52)<sup>**</sup>
<break/>10.35 (2.29)<sup>***</sup>
<break/>8.90 (1.30)<sup>&#x02020;</sup>
<break/>14.80 (2.90)<break/>16.20<sup>*</sup>
<break/>10.47 (4.68)<break/>10 (1.20)<break/>27.90 (1.85)</td></tr><tr><td align="left" colspan="5">
<sup>*</sup>Reference genotype group for all comparisons: <sup>**</sup>
<italic>p</italic> &#x0003c; 0.05, <sup>***</sup>
<italic>p</italic> &#x0003c; 0.005, <sup>&#x02020;</sup>
<italic>p</italic> &#x0003c; 0.001</td></tr><tr><td align="left" rowspan="3">Alhazzani et al. [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left" rowspan="3">Saudi Arabia<break/>&#x000a0;Epileptic patients taking PHT monotherapy: drug responsive (<italic>n</italic>&#x000a0;=&#x000a0;25), drug resistant (<italic>n</italic>&#x000a0;=&#x000a0;25)</td><td align="left" rowspan="3">300 mg PO daily &#x02265;1 month<break/>&#x000a0;Multiple samples collected over 12&#x000a0;h following dose</td><td align="left" rowspan="3">
<italic>MDR1 (ABCB1) C3435T</italic>
<break/>&#x000a0;Drug responsive<break/>&#x000a0;&#x000a0;C = 88<break/>&#x000a0;&#x000a0;T = 12<break/>Drug resistant<break/>&#x000a0;&#x000a0;C = 70<break/>&#x000a0;&#x000a0;T = 30</td><td align="left" rowspan="2" colspan="2">PK parameters<sup>b</sup>
</td><td align="left" colspan="3">Genotype</td></tr><tr><td align="left">CC</td><td align="left">CT</td><td align="left">TT</td></tr><tr><td align="left" colspan="2">
<italic>C</italic>
<sub>max</sub> (mg/mL)<break/>
<italic>T</italic>
<sub>max</sub> (h)<break/>AUC<sub>0&#x02013;12h</sub> (mg&#x000a0;h/mL)<break/>
<italic>t</italic>&#x000bd; (h)<break/>Cl (L/h)</td><td align="left">20.4 (0.29)<break/>6 (0.12)<break/>302 (0.45)<break/>19.2 (0.36)<break/>0.8 (0.11)</td><td align="left">28 (0.10)<break/>6 (0.08)<break/>545 (0.71)<break/>30.2 (0.12)<break/>0.5 (0.04)</td><td align="left">32 (0.16)<break/>6 (0.08)<break/>631 (0.48)<break/>33.3 (0.4)<break/>0.42 (0.21)</td></tr><tr><td align="left" rowspan="8">Ebid et al. [<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left" rowspan="8">Egypt<break/>&#x000a0;Epilepsy clinic outpatients taking PHT for partial (<italic>n</italic> = 43) or generalized tonic-clonic (<italic>n</italic> = 57) seizures; healthy volunteers from blood bank unit (<italic>n</italic> = 50)<break/>&#x000a0;&#x000a0;PHT phenotyping in epilepsy patients (<italic>n</italic> = 100)</td><td align="left" rowspan="8">Baseline dose<break/>&#x000a0;100&#x000a0;mg PO BID &#x02265;1&#x000a0;year<break/>Dose adjustment at 3&#x000a0;months: if drug resistant and <italic>C</italic>
<sub>tr</sub> &#x0003c;10&#x000a0;mg/L: 150&#x000a0;mg PO TID<break/>&#x000a0;If drug resistant and <italic>C</italic>
<sub>tr</sub> 10&#x02013;14&#x000a0;mg/L: 100&#x000a0;mg PO TID<break/>&#x000a0;If drug responsive and/or <italic>C</italic>
<sub>tr</sub> &#x02265;15&#x000a0;mg/L: stop PHT and end follow-up<break/>&#x000a0;<italic>C</italic>
<sub>tr</sub> collected pre-dose</td><td align="left" rowspan="8">
<italic>MDR1 (ABCB1) C3435T</italic>
<break/>&#x000a0;Drug responsive<break/>&#x000a0;&#x000a0;C = 36.5<break/>&#x000a0;&#x000a0;T = 63.5<break/>&#x000a0;Drug resistant<break/>&#x000a0;&#x000a0;C = 74.6<break/>&#x000a0;&#x000a0;T = 25.4<break/>&#x000a0;Healthy volunteers<break/>&#x000a0;&#x000a0;C = 48<break/>&#x000a0;&#x000a0;T = 52</td><td align="left" colspan="5">3-month evaluation (<italic>n</italic> = 100)</td></tr><tr><td align="left" colspan="2"/><td align="left" colspan="2">Responsive, <italic>n</italic> = 18 (%)</td><td align="left">Resistant, <italic>n</italic> = 82 (%)</td></tr><tr><td align="left" colspan="2">Serum PHT <italic>C</italic>
<sub>tr</sub>, mg/L<break/>&#x000a0;&#x0003c;10<break/>&#x000a0;10 to &#x0003c;15<break/>&#x000a0;&#x02265;15</td><td align="left" colspan="2">50<break/>44.4<break/>6.7</td><td align="left">79.3<break/>17.1<break/>3.7</td></tr><tr><td align="left" colspan="2">Genotype<break/>&#x000a0;CC<break/>&#x000a0;CT<break/>&#x000a0;TT</td><td align="left" colspan="2">0<break/>44.4<break/>55.6</td><td align="left">48.8<break/>40.2<break/>11</td></tr><tr><td align="left" colspan="5">6-month evaluation (<italic>n</italic> = 79)</td></tr><tr><td align="left"/><td align="left" colspan="3">Responsive, <italic>n</italic> = 19 (%)</td><td align="left">Resistant, <italic>n</italic> = 60 (%)</td></tr><tr><td align="left">Serum PHT <italic>C</italic>
<sub>tr</sub>, mg/L<break/>&#x000a0;&#x0003c;10<break/>&#x000a0;10 to &#x0003c;15<break/>&#x000a0;&#x02265;15</td><td align="left" colspan="3">10.5<break/>31.6<break/>57.9</td><td align="left">15<break/>68.3<break/>16.7</td></tr><tr><td align="left">Genotype<break/>&#x000a0;CC<break/>&#x000a0;CT<break/>&#x000a0;TT</td><td align="left" colspan="3">26.3<break/>47.4<break/>26.3</td><td align="left">58.3<break/>36.7<break/>5</td></tr></tbody></table><table-wrap-foot><p>
<italic>AUC</italic>
<sub><italic>0&#x02013;12h</italic></sub> area under the concentration&#x02013;time curve from 0 to 12 h post-dose, <italic>AVM</italic> arteriovenous malformation, <italic>BID</italic> twice daily, <italic>CBZ</italic> carbamazepine, <italic>CI</italic> confidence interval, <italic>Cl</italic> clearance, <italic>C</italic>
<sub><italic>max</italic></sub> maximum plasma concentration, <italic>C</italic>
<sub><italic>tr</italic></sub> trough concentration, <italic>CYP</italic> cytochrome P450, <italic>LTG</italic> lamotrigine, <italic>PHT</italic> phenytoin, <italic>p-HPPH</italic> 5-(<italic>p</italic>-hydroxyphenyl)-5-phenylhydantoin metabolite, <italic>PK</italic> pharmacokinetic, <italic>PO</italic> orally by mouth, <italic>SD</italic> standard deviation, <italic>SEM</italic> standard error of the mean, <italic>t&#x000bd;</italic> half-life, <italic>TID</italic> three times daily, <italic>T</italic>
<sub><italic>max</italic></sub> time to <italic>C</italic>
<sub>max</sub>, <italic>VPA</italic> valproic acid</p><p>
<sup>a</sup>From one individual, cannot calculate 95% CI, SD, or SEM</p><p>
<sup>b</sup>Mean (SEM) reported</p></table-wrap-foot></table-wrap>
</p><p id="Par19">Upon assessment, each of the five studies was rated to be of poor quality. The ratings of each study against the 14 quality assessment tool criteria are summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Factors contributing to poor quality ratings included: unclear descriptions of study subject selection, introducing potential for selection bias; insufficient reporting of study subjects&#x02019; baseline characteristics; relatively small sample sizes, limiting the power to assess the impact of polymorphic genotypes with low frequencies; and absence of adjustments for potential confounders that could affect phenytoin pharmacokinetics (e.g., antiepileptic polytherapy, concomitant medications, comorbid medical conditions, or serum albumin levels) or clinical outcomes (e.g., seizure control at baseline, seizure etiology, or type of seizure).<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Summary of methodological quality ratings of included studies<sup>a</sup>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Criteria</th><th align="left">Aynacioglu et al. [<xref ref-type="bibr" rid="CR42">42</xref>]</th><th align="left">Kerb et al. [<xref ref-type="bibr" rid="CR43">43</xref>]</th><th align="left">Ozkaynakci et al. [<xref ref-type="bibr" rid="CR44">44</xref>]</th><th align="left">Alhazzani et al. [<xref ref-type="bibr" rid="CR45">45</xref>]</th><th align="left">Ebid et al. [<xref ref-type="bibr" rid="CR46">46</xref>]</th></tr></thead><tbody><tr><td align="left">1. Research question or objective clearly stated</td><td align="left">Yes</td><td align="left">No</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">2. Study population clearly specified and defined</td><td align="left">No</td><td align="left">No</td><td align="left">No</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">3. At least 50% of eligible persons participate</td><td align="left">NR</td><td align="left">NR</td><td align="left">NR</td><td align="left">NR</td><td align="left">NR</td></tr><tr><td align="left">4a. All subjects selected from same or similar population and same time period</td><td align="left">CD</td><td align="left">CD</td><td align="left">CD</td><td align="left">CD</td><td align="left">CD</td></tr><tr><td align="left">4b. Inclusion and exclusion criteria pre-specified and uniformly applied</td><td align="left">NR</td><td align="left">NR</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">5. Sample size justification, power description, or variance and effect estimate provided</td><td align="left">No</td><td align="left">No</td><td align="left">No</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">6. Exposure<sup>b</sup> of interest measured prior to outcome(s) being measured</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">7. Timeframe sufficient to see association between exposure<sup>b</sup> and outcome if it existed</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">8. Study examined different levels of exposure<sup>b</sup> as related to outcome</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">9. Exposure<sup>b</sup> measures clearly defined, valid, reliable, and implemented consistently</td><td align="left">Yes</td><td align="left">CD</td><td align="left">Yes</td><td align="left">CD</td><td align="left">Yes</td></tr><tr><td align="left">10. Exposure<sup>b</sup> assessed more than once over time</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">11. Outcome measures clearly defined, valid, reliable, and implemented consistently</td><td align="left">Yes</td><td align="left">CD</td><td align="left">CD</td><td align="left">CD</td><td align="left">Yes</td></tr><tr><td align="left">12. Outcome assessors blinded to participant exposure status</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">13. Loss to follow-up after baseline was 20% or less</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">Yes</td></tr><tr><td align="left">14. Key potential confounding variables measured and adjusted for statistically</td><td align="left">No</td><td align="left">No</td><td align="left">No</td><td align="left">No</td><td align="left">No</td></tr></tbody></table><table-wrap-foot><p>
<italic>CD</italic> cannot determine, <italic>NA</italic> not applicable, <italic>NR</italic> not reported</p><p>
<sup>a</sup>Studies were rated against the 14 criteria of the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, from the National Institutes of Health, National Heart, Lung, and Blood Institute [<xref ref-type="bibr" rid="CR16">16</xref>]</p><p>
<sup>b</sup>Exposure was defined as study participants&#x02019; allelic make-up for the polymorphism of interest</p></table-wrap-foot></table-wrap>
</p><p id="Par20">A total of 82 studies were conducted within the MENA region and investigated the prevalence of <italic>CYP2C9</italic>, <italic>CYP2C19</italic>, and/or <italic>MDR1</italic> variant alleles [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR121">121</xref>]. These studies were included in the secondary part of the review. Specific single nucleotide polymorphisms reviewed were<italic>: CYP2C9*1</italic>, <italic>*2</italic>, and <italic>*3</italic>; <italic>CYP2C19*1</italic>, <italic>*2</italic>, and <italic>*3</italic>; and <italic>MDR1 (ABCB1)</italic> C3435T. The study populations and computed genotypic and allelic frequencies for <italic>CYP2C9</italic>, <italic>CYP2C19</italic>, and <italic>MDR1</italic> are summarized in Tables&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, <xref rid="Tab4" ref-type="table">4</xref>, and <xref rid="Tab5" ref-type="table">5</xref>, respectively.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Genotypic and allelic frequencies of <italic>CYP2C9</italic> in the Middle East and North Africa region</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">References</th><th align="left" rowspan="2">Country</th><th align="left" rowspan="2">Study population</th><th align="left" rowspan="2">Sample size</th><th align="left" colspan="6">Genotypic frequencies (%)</th><th align="left" colspan="3">Allelic frequencies (%)</th></tr><tr><th align="left">*1/*1</th><th align="left">*1/*2</th><th align="left">*1/*3</th><th align="left">*2/*2</th><th align="left">*2/*3</th><th align="left">*3/*3</th><th align="left">*1</th><th align="left">*2</th><th align="left">*3</th></tr></thead><tbody><tr><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">Egypt</td><td align="left">Healthy volunteers</td><td char="." align="char">247</td><td char="." align="char">66.4</td><td align="left">19.0</td><td char="." align="char">11.7</td><td align="left">2.4</td><td align="left">0</td><td char="." align="char">0.4</td><td char="." align="char">81.8</td><td align="left">11.9</td><td align="left">6.3</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">Egypt</td><td align="left">Healthy volunteers (<italic>n</italic> = 154), patients taking maintenance warfarin (<italic>n</italic> = 46)</td><td char="." align="char">200</td><td char="." align="char">81.5</td><td align="left">4.5</td><td char="." align="char">8.5</td><td align="left">4.5</td><td align="left">0.5</td><td char="." align="char">0.5</td><td char="." align="char">88.0</td><td align="left">7.0</td><td align="left">5.0</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left" rowspan="2">Egypt</td><td align="left">Warfarin-resistant patients</td><td char="." align="char">41</td><td char="." align="char">60.9</td><td align="left">19.5</td><td char="." align="char">19.5</td><td align="left">0</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">80.4</td><td align="left">9.8</td><td align="left">9.8</td></tr><tr><td align="left">Warfarin-responsive patients</td><td char="." align="char">30</td><td char="." align="char">73.3</td><td align="left">20.0</td><td char="." align="char">6.7</td><td align="left">0</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">86.7</td><td align="left">10.0</td><td align="left">3.3</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left">Egypt</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">63</td><td char="." align="char">76.2</td><td align="left">7.9</td><td char="." align="char">6.3</td><td align="left">3.2</td><td align="left">0</td><td char="." align="char">6.3</td><td char="." align="char">83.4</td><td align="left">7.1</td><td align="left">9.5</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left">Egypt</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">84</td><td char="." align="char">83.3</td><td align="left">NA</td><td char="." align="char">11.9</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">4.8</td><td char="." align="char">89.3</td><td align="left">NA</td><td align="left">10.7</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">Egypt<sup>a</sup>
</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">207</td><td char="." align="char">62.6</td><td align="left">17.4</td><td char="." align="char">11.8</td><td align="left">1.0</td><td align="left">4.1</td><td char="." align="char">1.0</td><td char="." align="char">74.2</td><td align="left">11.1</td><td align="left">8.5</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">Iran</td><td align="left">Healthy volunteers</td><td char="." align="char">200</td><td char="." align="char">82.0</td><td align="left">10.5</td><td char="." align="char">0</td><td align="left">7.5</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">87.2</td><td align="left">12.8</td><td align="left">0</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left" rowspan="2">Iran</td><td align="left">Healthy volunteers</td><td char="." align="char">50</td><td char="." align="char">82.0</td><td align="left">12.0</td><td char="." align="char">6.0</td><td align="left">0</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">91.0</td><td align="left">6.0</td><td align="left">3.0</td></tr><tr><td align="left">Patients taking maintenance valproic acid</td><td char="." align="char">68</td><td char="." align="char">80.9</td><td align="left">11.8</td><td char="." align="char">4.4</td><td align="left">1.5</td><td align="left">1.5</td><td char="." align="char">0</td><td char="." align="char">89.0</td><td align="left">8.1</td><td align="left">2.9</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left" rowspan="2">Iran</td><td align="left">Warfarin-sensitive patients</td><td char="." align="char">21</td><td char="." align="char">19.0</td><td align="left">66.7</td><td char="." align="char">14.3</td><td align="left">0</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">52.4</td><td align="left">47.6</td><td align="left">NA</td></tr><tr><td align="left">Patients with normal warfarin response</td><td char="." align="char">37</td><td char="." align="char">75.7</td><td align="left">21.6</td><td char="." align="char">2.7</td><td align="left">0</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">86.5</td><td align="left">13.5</td><td align="left">NA</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">Iran</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">100</td><td char="." align="char">39.0</td><td align="left">41.0</td><td char="." align="char">9.0</td><td align="left">2.0</td><td align="left">9.0</td><td char="." align="char">0</td><td char="." align="char">64.0</td><td align="left">27.0</td><td align="left">9.0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left">Jordan</td><td align="left">Healthy volunteers</td><td char="." align="char">263</td><td char="." align="char">62.7</td><td align="left">21.7</td><td char="." align="char">12.2</td><td align="left">1.9</td><td align="left">1.5</td><td char="." align="char">0</td><td char="." align="char">79.7</td><td align="left">13.5</td><td align="left">6.8</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR58">58</xref>]</td><td align="left">Kuwait</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">108</td><td char="." align="char">69.4</td><td align="left">21.3</td><td char="." align="char">6.5</td><td align="left">0</td><td align="left">2.8</td><td char="." align="char">0</td><td char="." align="char">83.4</td><td align="left">12.0</td><td align="left">4.6</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR59">59</xref>]</td><td align="left">Libya</td><td align="left">Healthy volunteers</td><td char="." align="char">161</td><td char="." align="char">65.8</td><td align="left">14.9</td><td char="." align="char">13.7</td><td align="left">1.9</td><td align="left">2.5</td><td char="." align="char">1.2</td><td char="." align="char">80.1</td><td align="left">10.6</td><td align="left">9.3</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left">Libya</td><td align="left">Patients taking maintenance VKA</td><td char="." align="char">231</td><td char="." align="char">60.6</td><td align="left">22.5</td><td char="." align="char">10.0</td><td align="left">2.2</td><td align="left">3.9</td><td char="." align="char">0.9</td><td char="." align="char">76.8</td><td align="left">15.4</td><td align="left">7.8</td></tr><tr><td align="left" rowspan="3">[<xref ref-type="bibr" rid="CR61">61</xref>]</td><td align="left" rowspan="3">Morocco</td><td align="left">Low-dose acenocoumarol</td><td char="." align="char">20</td><td char="." align="char">55.0</td><td align="left">25.0</td><td char="." align="char">5.0</td><td align="left">10.0</td><td align="left">0</td><td char="." align="char">5.0</td><td char="." align="char">70.0</td><td align="left">22.5</td><td align="left">7.5</td></tr><tr><td align="left">Medium-dose acenocoumarol</td><td char="." align="char">58</td><td char="." align="char">72.4</td><td align="left">19.0</td><td char="." align="char">6.9</td><td align="left">1.7</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">85.4</td><td align="left">11.2</td><td align="left">3.4</td></tr><tr><td align="left">High-dose acenocoumarol</td><td char="." align="char">36</td><td char="." align="char">94.4</td><td align="left">2.8</td><td char="." align="char">0</td><td align="left">2.8</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">95.8</td><td align="left">4.2</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td><td align="left">Oman<sup>a</sup>
</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">212</td><td char="." align="char">73.6</td><td align="left">11.3</td><td char="." align="char">8.5</td><td align="left">NA</td><td align="left">2.4</td><td char="." align="char">0.9</td><td char="." align="char">84.2</td><td align="left">6.8</td><td align="left">6.4</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR63">63</xref>]</td><td align="left">Oman</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">189</td><td char="." align="char">80.4</td><td align="left">12.7</td><td char="." align="char">5.8</td><td align="left">1.1</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">89.6</td><td align="left">7.5</td><td align="left">2.9</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR64">64</xref>]</td><td align="left">Saudi Arabia</td><td align="left">Healthy volunteers</td><td char="." align="char">131</td><td char="." align="char">68.7</td><td align="left">26.7</td><td char="." align="char">4.6</td><td align="left">0</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">84.3</td><td align="left">13.4</td><td align="left">2.3</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR65">65</xref>]</td><td align="left">Saudi Arabia</td><td align="left">Healthy volunteers</td><td char="." align="char">192</td><td char="." align="char">64.1</td><td align="left">17.2</td><td char="." align="char">13.0</td><td align="left">2.1</td><td align="left">2.1</td><td char="." align="char">1.6</td><td char="." align="char">79.2</td><td align="left">11.7</td><td align="left">9.1</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR66">66</xref>]</td><td align="left">Sudan<sup>a</sup>
</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">203</td><td char="." align="char">71.9</td><td align="left">8.9</td><td char="." align="char">0</td><td align="left">0</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">84.0</td><td align="left">4.9</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left">Tunisia<sup>a</sup>
</td><td align="left">Healthy volunteers</td><td char="." align="char">258</td><td char="." align="char">61.6</td><td align="left">19.4</td><td char="." align="char">13.2</td><td align="left">2.7</td><td align="left">3.1</td><td char="." align="char">0</td><td char="." align="char">77.9</td><td align="left">14.0</td><td align="left">8.1</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">Turkey</td><td align="left">Healthy volunteers</td><td char="." align="char">96</td><td char="." align="char">66.7</td><td align="left">13.5</td><td char="." align="char">15.6</td><td align="left">3.1</td><td align="left">0</td><td char="." align="char">1.0</td><td char="." align="char">81.2</td><td align="left">9.9</td><td align="left">8.9</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR68">68</xref>]</td><td align="left">Turkey</td><td align="left">Healthy volunteers</td><td char="." align="char">64</td><td char="." align="char">64.0</td><td align="left">14.1</td><td char="." align="char">15.6</td><td align="left">3.1</td><td align="left">0</td><td char="." align="char">3.1</td><td char="." align="char">78.9</td><td align="left">10.2</td><td align="left">10.9</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR69">69</xref>]</td><td align="left">Turkey</td><td align="left">Healthy volunteers</td><td char="." align="char">85</td><td char="." align="char">68.2</td><td align="left">11.8</td><td char="." align="char">14.1</td><td align="left">3.5</td><td align="left">1.2</td><td char="." align="char">1.2</td><td char="." align="char">81.2</td><td align="left">10.0</td><td align="left">8.8</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">Turkey</td><td align="left">Healthy volunteers (<italic>n</italic> = 218), outpatients with variable diagnoses (<italic>n</italic> = 280)</td><td char="." align="char">499</td><td char="." align="char">61.7</td><td align="left">18.0</td><td char="." align="char">17.2</td><td align="left">1.0</td><td align="left">1.1</td><td char="." align="char">0.8</td><td char="." align="char">79.4</td><td align="left">10.6</td><td align="left">10.0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left">Turkey</td><td align="left">Outpatients of epilepsy clinic</td><td char="." align="char">102</td><td char="." align="char">78.4</td><td align="left">14.7</td><td char="." align="char">6.9</td><td align="left">0</td><td align="left">0</td><td char="." align="char">0</td><td char="." align="char">89.2</td><td align="left">7.4</td><td align="left">3.4</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR70">70</xref>]</td><td align="left">Turkey<sup>a</sup>
</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">205</td><td char="." align="char">60.0</td><td align="left">18.0</td><td char="." align="char">13.7</td><td align="left">1.5</td><td align="left">3.9</td><td char="." align="char">1.0</td><td char="." align="char">76.8</td><td align="left">12.7</td><td align="left">9.8</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR71">71</xref>]</td><td align="left">Turkey</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">100</td><td char="." align="char">50.0</td><td align="left">21.0</td><td char="." align="char">24.0</td><td align="left">0</td><td align="left">5.0</td><td char="." align="char">0</td><td char="." align="char">72.5</td><td align="left">13.0</td><td align="left">14.5</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR72">72</xref>]</td><td align="left">Turkey</td><td align="left">Patients taking maintenance anticoagulant</td><td char="." align="char">292</td><td char="." align="char">56.5</td><td align="left">23.0</td><td char="." align="char">8.6</td><td align="left">3.0</td><td align="left">7.2</td><td char="." align="char">1.7</td><td char="." align="char">72.2</td><td align="left">18.2</td><td align="left">9.6</td></tr></tbody></table><table-wrap-foot><p>
<italic>CYP</italic> cytochrome P450, <italic>NA</italic> not assessed, <italic>VKA</italic> vitamin-K antagonist, <italic>VPA</italic> valproic acid</p><p>
<sup>a</sup>Additional CYP2C9 alleles assessed; therefore, percentages do not add to 100%</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Genotypic and allelic frequencies of <italic>CYP2C19</italic> in the Middle East and North Africa region</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">References</th><th align="left" rowspan="2">Country</th><th align="left" rowspan="2">Study population</th><th align="left" rowspan="2">Sample size</th><th align="left" colspan="6">Genotypic frequencies (%)</th><th align="left" colspan="3">Allelic frequencies (%)</th></tr><tr><th align="left">*1/*1</th><th align="left">*1/*2</th><th align="left">*1/*3</th><th align="left">*2/*2</th><th align="left">*2/*3</th><th align="left">*3/*3</th><th align="left">*1</th><th align="left">*2</th><th align="left">*3</th></tr></thead><tbody><tr><td align="left">[<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left">Bahrain<sup>a</sup>
</td><td align="left">Healthy volunteers</td><td char="." align="char">75</td><td align="left">33.3</td><td char="." align="char">33.3</td><td align="left">NA</td><td char="." align="char">8.0</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">53.3</td><td char="." align="char">26.0</td><td align="left">NA</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">Egypt</td><td align="left">Healthy volunteers</td><td char="." align="char">247</td><td align="left">78.5</td><td char="." align="char">20.2</td><td align="left">0.4</td><td char="." align="char">0.8</td><td align="left">0</td><td align="left">0</td><td char="." align="char">88.9</td><td char="." align="char">10.9</td><td align="left">0.2</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR73">73</xref>]</td><td align="left">Egypt</td><td align="left">Male agricultural workers</td><td char="." align="char">120</td><td align="left">93.3</td><td char="." align="char">5.8</td><td align="left">NA</td><td char="." align="char">0.8</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">96.2</td><td char="." align="char">3.8</td><td align="left">NA</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR74">74</xref>]</td><td align="left" rowspan="2">Gaza Strip</td><td align="left">Children with hematological malignancy</td><td char="." align="char">52</td><td align="left">80.8</td><td char="." align="char">15.4</td><td align="left">1.9</td><td char="." align="char">1.9</td><td align="left">0</td><td align="left">0</td><td char="." align="char">89.4</td><td char="." align="char">9.6</td><td align="left">1.0</td></tr><tr><td align="left">Healthy volunteers</td><td char="." align="char">200</td><td align="left">86.5</td><td char="." align="char">6.5</td><td align="left">1.5</td><td char="." align="char">3</td><td align="left">0.5</td><td align="left">2.0</td><td char="." align="char">90.5</td><td char="." align="char">6.5</td><td align="left">3.0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">Iran</td><td align="left">Healthy volunteers</td><td char="." align="char">200</td><td align="left">75.0</td><td char="." align="char">22.0</td><td align="left">0</td><td char="." align="char">3.0</td><td align="left">0</td><td align="left">0</td><td char="." align="char">86.0</td><td char="." align="char">14.0</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR75">75</xref>]</td><td align="left">Iran<sup>a</sup>
</td><td align="left">Healthy volunteers</td><td char="." align="char">180</td><td align="left">41.7</td><td char="." align="char">18.3</td><td align="left">NA</td><td char="." align="char">2.2</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">65.3</td><td char="." align="char">13.1</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left">Iran</td><td align="left">Healthy volunteers of Baluch descent</td><td char="." align="char">140</td><td align="left">78.6</td><td char="." align="char">20.0</td><td align="left">0.7</td><td char="." align="char">0</td><td align="left">0</td><td align="left">0.7</td><td char="." align="char">88.9</td><td char="." align="char">10.0</td><td align="left">1.1</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR76">76</xref>]</td><td align="left">Iran</td><td align="left">Patients with erosive reflux esophagitis</td><td char="." align="char">82</td><td align="left">70.7</td><td char="." align="char">24.3</td><td align="left">3.7</td><td char="." align="char">1.3</td><td align="left">0</td><td align="left">0</td><td char="." align="char">84.8</td><td char="." align="char">13.4</td><td align="left">1.8</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">Iran</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">99</td><td align="left">76.8</td><td char="." align="char">21.2</td><td align="left">0.1</td><td char="." align="char">0</td><td align="left">0.1</td><td align="left">0</td><td char="." align="char">87.9</td><td char="." align="char">11.1</td><td align="left">1.0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR77">77</xref>]</td><td align="left">Iran</td><td align="left">Patients taking clopidogrel for elective PCI</td><td char="." align="char">112</td><td align="left" colspan="6">NR</td><td char="." align="char">89.0</td><td align="left">10.1</td><td char="." align="char">0.9</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR78">78</xref>]</td><td align="left">Iran</td><td align="left">Patients with PCI for CAD</td><td char="." align="char">43</td><td align="left">72.1</td><td char="." align="char">23.3</td><td align="left">NA</td><td char="." align="char">4.7</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">83.7</td><td char="." align="char">16.3</td><td align="left">NA</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR79">79</xref>]</td><td align="left" rowspan="2">Iran</td><td align="left">Patients with in-stent restenosis while taking appropriate DAPT for PCI</td><td char="." align="char">50</td><td align="left">86.0</td><td char="." align="char">14.0</td><td align="left">NA</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">93.0</td><td char="." align="char">7.0</td><td align="left">NA</td></tr><tr><td align="left">Patients without in-stent restenosis while taking DAPT for PCI</td><td char="." align="char">50</td><td align="left">92.0</td><td char="." align="char">8.0</td><td align="left">NA</td><td char="." align="char">0</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">96.0</td><td char="." align="char">4.0</td><td align="left">NA</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR80">80</xref>]</td><td align="left">Israel</td><td align="left">Healthy volunteers</td><td char="." align="char">140</td><td align="left">70.7</td><td char="." align="char">25.0</td><td align="left">1.4</td><td char="." align="char">2.9</td><td align="left">0</td><td align="left">0</td><td char="." align="char">83.9</td><td char="." align="char">15.4</td><td align="left">0.7</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR81">81</xref>]</td><td align="left" rowspan="2">Israel</td><td align="left">Volunteers of Yemenite descent</td><td char="." align="char">36</td><td align="left">77.8</td><td char="." align="char">19.4</td><td align="left">0</td><td char="." align="char">2.8</td><td align="left">0</td><td align="left">0</td><td char="." align="char">87.5</td><td char="." align="char">12.5</td><td align="left">0</td></tr><tr><td align="left">Volunteers of Bedouin descent</td><td char="." align="char">50</td><td align="left">76.0</td><td char="." align="char">20.0</td><td align="left">2.0</td><td char="." align="char">2.0</td><td align="left">0</td><td align="left">0</td><td char="." align="char">87.0</td><td char="." align="char">12.0</td><td align="left">1.0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left">Jordan</td><td align="left">Healthy volunteers</td><td char="." align="char">158</td><td align="left">78.5</td><td char="." align="char">18.4</td><td align="left">0</td><td char="." align="char">3.2</td><td align="left">0</td><td align="left">0</td><td char="." align="char">87.7</td><td char="." align="char">12.3</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR82">82</xref>]</td><td align="left">Jordan</td><td align="left">Healthy male volunteers</td><td char="." align="char">78</td><td align="left">74.4</td><td char="." align="char">19.2</td><td align="left">0</td><td char="." align="char">6.4</td><td align="left">0</td><td align="left">0</td><td char="." align="char">84.0</td><td char="." align="char">16.0</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left">Kuwait<sup>a</sup>
</td><td align="left">Healthy volunteers</td><td char="." align="char">100</td><td align="left">41.0</td><td char="." align="char">35.0</td><td align="left">NA</td><td char="." align="char">3.0</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">61.5</td><td char="." align="char">22.0</td><td align="left">NA</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR83">83</xref>]</td><td align="left">Lebanon</td><td align="left">Healthy volunteers</td><td char="." align="char">161</td><td align="left">75.8</td><td char="." align="char">20.5</td><td align="left">0.6</td><td char="." align="char">3.1</td><td align="left">0</td><td align="left">0</td><td char="." align="char">86.3</td><td char="." align="char">13.4</td><td align="left">0.3</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR84">84</xref>]</td><td align="left">Saudi Arabia<sup>a</sup>
</td><td align="left">Healthy volunteers</td><td char="." align="char">201</td><td align="left">40.3</td><td char="." align="char">14.4</td><td align="left">NA</td><td char="." align="char">0.005</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">62.9</td><td char="." align="char">11.2</td><td align="left">NA</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR85">85</xref>]</td><td align="left">Saudi Arabia</td><td align="left">Healthy military recruits</td><td char="." align="char">97</td><td align="left" colspan="6">NR</td><td char="." align="char">87.0</td><td align="left">13.0</td><td char="." align="char">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR86">86</xref>]</td><td align="left">Saudi Arabia</td><td align="left">Patients taking clopidogrel for ACS</td><td char="." align="char">90</td><td align="left">67.0</td><td char="." align="char">3.0</td><td align="left">0</td><td char="." align="char">32.0</td><td align="left">0</td><td align="left">0</td><td char="." align="char">67.8</td><td char="." align="char">32.2</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left">Tunisia<sup>a</sup>
</td><td align="left">Healthy volunteers</td><td char="." align="char">258</td><td align="left">47.3</td><td char="." align="char">12.8</td><td align="left">NA</td><td char="." align="char">0.3</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">69.8</td><td char="." align="char">8.9</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">Turkey</td><td align="left">Healthy volunteers</td><td char="." align="char">94</td><td align="left">78.1</td><td char="." align="char">16.7</td><td align="left">NA</td><td char="." align="char">3.1</td><td align="left">NA</td><td align="left">NA</td><td char="." align="char">88.3</td><td char="." align="char">11.7</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR87">87</xref>]</td><td align="left">Turkey</td><td align="left">Healthy volunteers</td><td char="." align="char">404</td><td align="left">76.0</td><td char="." align="char">22.3</td><td align="left">0.7</td><td char="." align="char">1.0</td><td align="left">0</td><td align="left">0</td><td char="." align="char">87.5</td><td char="." align="char">12.1</td><td align="left">0.4</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left">Turkey</td><td align="left">Outpatients of epilepsy clinic</td><td char="." align="char">102</td><td align="left">55.9</td><td char="." align="char">17.6</td><td align="left">10.8</td><td char="." align="char">5.9</td><td align="left">9.8</td><td align="left">0</td><td char="." align="char">70.1</td><td char="." align="char">19.6</td><td align="left">10.3</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR88">88</xref>]</td><td align="left">Turkey<sup>a</sup>
</td><td align="left">Children, 2&#x02013;18 years old</td><td char="." align="char">244</td><td align="left">44.3</td><td char="." align="char">12.3</td><td align="left">0</td><td char="." align="char">1.2</td><td align="left">0</td><td align="left">0</td><td char="." align="char">65.6</td><td char="." align="char">10.0</td><td align="left">0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR89">89</xref>]</td><td align="left">Turkey</td><td align="left">Patients taking clopidogrel for ICVD</td><td char="." align="char">51</td><td align="left">70.6</td><td char="." align="char">25.5</td><td align="left">0</td><td char="." align="char">3.9</td><td align="left">0</td><td align="left">0</td><td char="." align="char">83.3</td><td char="." align="char">16.7</td><td align="left">0</td></tr></tbody></table><table-wrap-foot><p>
<italic>ACS</italic> acute coronary syndrome, <italic>CAD</italic> coronary artery disease, <italic>CYP</italic> cytochrome P450, <italic>DAPT</italic> dual anti-platelet therapy, <italic>ICVD</italic> ischemic cerebrovascular disease, <italic>MACE</italic> major adverse cardiac event, <italic>NA</italic> not assessed, <italic>NR</italic> not reported, <italic>PCI</italic> percutaneous coronary intervention</p><p>
<sup>a</sup>Additional CYP2C19 alleles assessed; therefore, percentages do not add to 100%</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Genotypic and allelic frequencies of <italic>MDR1</italic> (<italic>ABCB1</italic>) C3435T in the Middle East and North Africa region</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">References</th><th align="left" rowspan="2">Country</th><th align="left" rowspan="2">Study population</th><th align="left" rowspan="2">Sample size</th><th align="left" colspan="3">Genotypic frequencies (%)</th><th align="left" colspan="2">Allelic frequencies (%)</th></tr><tr><th align="left">CC</th><th align="left">CT</th><th align="left">TT</th><th align="left">C</th><th align="left">T</th></tr></thead><tbody><tr><td align="left" rowspan="3">[<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left" rowspan="3">Egypt</td><td align="left">Healthy volunteers</td><td char="." align="char">50</td><td align="left">24.0</td><td char="." align="char">48.0</td><td char="." align="char">28.0</td><td char="." align="char">48.0</td><td char="." align="char">52.0</td></tr><tr><td align="left">Patients with drug-responsive epilepsy</td><td char="." align="char">37</td><td align="left">13.5</td><td char="." align="char">46.0</td><td char="." align="char">40.5</td><td char="." align="char">36.5</td><td char="." align="char">63.5</td></tr><tr><td align="left">Patients with drug-resistant epilepsy</td><td char="." align="char">63</td><td align="left">55.6</td><td char="." align="char">38.1</td><td char="." align="char">6.3</td><td char="." align="char">74.6</td><td char="." align="char">25.4</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR90">90</xref>]</td><td align="left" rowspan="2">Egypt</td><td align="left">Patients taking clopidogrel for ACS or PCI who experienced MACE</td><td char="." align="char">84</td><td align="left">39.3</td><td char="." align="char">47.6</td><td char="." align="char">13.1</td><td char="." align="char">63.1</td><td char="." align="char">36.9</td></tr><tr><td align="left">Patients taking clopidogrel for ACS or PCI who did not experience MACE</td><td char="." align="char">106</td><td align="left">37.7</td><td char="." align="char">44.3</td><td char="." align="char">17.9</td><td char="." align="char">59.9</td><td char="." align="char">40.1</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR91">91</xref>]</td><td align="left">Egypt</td><td align="left">Patients taking maintenance warfarin</td><td char="." align="char">84</td><td align="left">29.8</td><td char="." align="char">54.8</td><td char="." align="char">15.4</td><td char="." align="char">57.1</td><td char="." align="char">42.9</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR92">92</xref>]</td><td align="left">Egypt</td><td align="left">Patients with hypercholesterolemia</td><td char="." align="char">50</td><td align="left">38.0</td><td char="." align="char">40.0</td><td char="." align="char">22.0</td><td char="." align="char">58.0</td><td char="." align="char">42.0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR93">93</xref>]</td><td align="left">Egypt</td><td align="left">Patients taking imatinib for newly diagnosed Philadelphia chromosome-positive CML</td><td char="." align="char">100</td><td align="left">44.0</td><td char="." align="char">47.0</td><td char="." align="char">9.0</td><td char="." align="char">67.5</td><td char="." align="char">32.5</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR94">94</xref>]</td><td align="left" rowspan="2">Egypt</td><td align="left">Healthy child volunteers</td><td char="." align="char">35</td><td align="left">28.6</td><td char="." align="char">48.6</td><td char="." align="char">22.9</td><td char="." align="char">47.1</td><td char="." align="char">52.9</td></tr><tr><td align="left">Children with immune thrombocytopenia</td><td char="." align="char">48</td><td align="left">8.3</td><td char="." align="char">62.5</td><td char="." align="char">27.1</td><td char="." align="char">67.6</td><td char="." align="char">32.4</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR95">95</xref>]</td><td align="left">Iran</td><td align="left">Patients admitted for primary care</td><td char="." align="char">933</td><td align="left">31.6</td><td char="." align="char">64.5</td><td char="." align="char">3.9</td><td char="." align="char">49.1</td><td char="." align="char">50.9</td></tr><tr><td align="left" rowspan="3">[<xref ref-type="bibr" rid="CR96">96</xref>]</td><td align="left" rowspan="3">Iran</td><td align="left">Healthy volunteers</td><td char="." align="char">200</td><td align="left">23.5</td><td char="." align="char">45.0</td><td char="." align="char">31.5</td><td char="." align="char">46.0</td><td char="." align="char">54.0</td></tr><tr><td align="left">Patients with drug-responsive epilepsy</td><td char="." align="char">200</td><td align="left">16.0</td><td char="." align="char">40.0</td><td char="." align="char">44.0</td><td char="." align="char">36.0</td><td char="." align="char">64.0</td></tr><tr><td align="left">Patients with drug-resistant epilepsy</td><td char="." align="char">132</td><td align="left">25.7</td><td char="." align="char">41.7</td><td char="." align="char">32.6</td><td char="." align="char">46.6</td><td char="." align="char">53.4</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR97">97</xref>]</td><td align="left" rowspan="2">Iran</td><td align="left">Iranian Azeri Turkish volunteers</td><td char="." align="char">92</td><td align="left">19.6</td><td char="." align="char">53.3</td><td char="." align="char">27.2</td><td char="." align="char">46.2</td><td char="." align="char">53.8</td></tr><tr><td align="left">Iranian Azeri Turkish patients with Beh&#x000e7;et&#x02019;s disease</td><td char="." align="char">69</td><td align="left">18.8</td><td char="." align="char">46.4</td><td char="." align="char">34.8</td><td char="." align="char">42.0</td><td char="." align="char">58.0</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR98">98</xref>]</td><td align="left" rowspan="2">Iran</td><td align="left">Healthy female volunteers</td><td char="." align="char">200</td><td align="left">70.5</td><td char="." align="char">25.0</td><td char="." align="char">4.5</td><td char="." align="char">83.0</td><td char="." align="char">17.0</td></tr><tr><td align="left">Female patients with breast cancer</td><td char="." align="char">100</td><td align="left">75.0</td><td char="." align="char">16.0</td><td char="." align="char">9.0</td><td char="." align="char">83.0</td><td char="." align="char">17.0</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR99">99</xref>]</td><td align="left" rowspan="2">Iran</td><td align="left">Healthy female volunteers</td><td char="." align="char">54</td><td align="left">18.5</td><td char="." align="char">55.6</td><td char="." align="char">25.9</td><td char="." align="char">47.0</td><td char="." align="char">53.0</td></tr><tr><td align="left">Female patients with breast cancer</td><td char="." align="char">50</td><td align="left">20.0</td><td char="." align="char">54.0</td><td char="." align="char">26.0</td><td char="." align="char">46.3</td><td char="." align="char">53.7</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR100">100</xref>]</td><td align="left" rowspan="2">Iran</td><td align="left">Healthy female volunteers</td><td char="." align="char">77</td><td align="left">15.6</td><td char="." align="char">58.4</td><td char="." align="char">26.0</td><td char="." align="char">44.8</td><td char="." align="char">55.2</td></tr><tr><td align="left">Female patients with breast cancer</td><td char="." align="char">106</td><td align="left">15.1</td><td char="." align="char">53.7</td><td char="." align="char">31.1</td><td char="." align="char">42.0</td><td char="." align="char">58.0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR101">101</xref>]</td><td align="left">Jordan</td><td align="left">Healthy volunteers</td><td char="." align="char">100</td><td align="left">17.0</td><td char="." align="char">50.0</td><td char="." align="char">33.0</td><td char="." align="char">42.0</td><td char="." align="char">58.0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR102">102</xref>]</td><td align="left">Jordan</td><td align="left">Patients of ear, nose, and throat clinic</td><td char="." align="char">251</td><td align="left">16.3</td><td char="." align="char">48.2</td><td char="." align="char">35.4</td><td char="." align="char">40.4</td><td char="." align="char">59.6</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR103">103</xref>]</td><td align="left">Jordan</td><td align="left">Patients receiving methotrexate for RA</td><td char="." align="char">159</td><td align="left">37.7</td><td char="." align="char">45.3</td><td char="." align="char">17.0</td><td char="." align="char">60.4</td><td char="." align="char">39.6</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR104">104</xref>]</td><td align="left" rowspan="2">Jordan</td><td align="left">Healthy female volunteers</td><td char="." align="char">150</td><td align="left">26.7</td><td char="." align="char">43.3</td><td char="." align="char">30.0</td><td char="." align="char">48.3</td><td char="." align="char">51.7</td></tr><tr><td align="left">Female patients with breast cancer</td><td char="." align="char">150</td><td align="left">45.3</td><td char="." align="char">41.3</td><td char="." align="char">13.3</td><td char="." align="char">66.0</td><td char="." align="char">34.0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR105">105</xref>]</td><td align="left">Lebanon</td><td align="left">Children with ALL</td><td char="." align="char">127</td><td align="left">27.6</td><td char="." align="char">44.1</td><td char="." align="char">28.3</td><td char="." align="char">49.6</td><td char="." align="char">50.4</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR106">106</xref>]</td><td align="left">Morocco</td><td align="left">Healthy volunteers</td><td char="." align="char">100</td><td align="left">39.0</td><td char="." align="char">51.0</td><td char="." align="char">10.0</td><td char="." align="char">64.5</td><td char="." align="char">35.5</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR107">107</xref>]</td><td align="left">Saudi Arabia</td><td align="left">Healthy volunteers</td><td char="." align="char">179</td><td align="left">35.2</td><td char="." align="char">45.2</td><td char="." align="char">19.6</td><td char="." align="char">57.8</td><td char="." align="char">42.2</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR108">108</xref>]</td><td align="left" rowspan="2">Saudi Arabia</td><td align="left">Healthy female volunteers</td><td char="." align="char">100</td><td align="left">93.0</td><td char="." align="char">5.0</td><td char="." align="char">2.0</td><td char="." align="char">95.5</td><td char="." align="char">4.5</td></tr><tr><td align="left">Female patients with breast cancer</td><td char="." align="char">100</td><td align="left">73.0</td><td char="." align="char">11.0</td><td char="." align="char">16.0</td><td char="." align="char">78.5</td><td char="." align="char">21.5</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left" rowspan="2">Saudi Arabia</td><td align="left">Patients with PHT-responsive epilepsy</td><td char="." align="char">25</td><td align="left">80.0</td><td char="." align="char" colspan="2">20.0</td><td char="." align="char">88.0</td><td char="." align="char">12.0</td></tr><tr><td align="left">Patients with PHT-resistant epilepsy</td><td char="." align="char">25</td><td align="left">52.0</td><td char="." align="char" colspan="2">48.0</td><td char="." align="char">70.0</td><td char="." align="char">30.0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">Turkey</td><td align="left">Healthy volunteers</td><td char="." align="char">96</td><td align="left">29.2</td><td char="." align="char">46.9</td><td char="." align="char">24.0</td><td char="." align="char">52.6</td><td char="." align="char">47.4</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR109">109</xref>]</td><td align="left">Turkey</td><td align="left">Healthy volunteers</td><td char="." align="char">107</td><td align="left">27.1</td><td char="." align="char">41.1</td><td char="." align="char">31.8</td><td char="." align="char">47.7</td><td char="." align="char">52.3</td></tr><tr><td align="left" rowspan="3">[<xref ref-type="bibr" rid="CR110">110</xref>]</td><td align="left" rowspan="3">Turkey</td><td align="left">Healthy volunteers</td><td char="." align="char">174</td><td align="left">28.2</td><td char="." align="char">46.0</td><td char="." align="char">25.9</td><td char="." align="char">51.1</td><td char="." align="char">48.9</td></tr><tr><td align="left">Patients with CBZ-responsive epilepsy</td><td char="." align="char">53</td><td align="left">30.2</td><td char="." align="char">54.7</td><td char="." align="char">15.1</td><td char="." align="char">57.5</td><td char="." align="char">42.5</td></tr><tr><td align="left">Patients with CBZ-resistant epilepsy</td><td char="." align="char">44</td><td align="left">29.5</td><td char="." align="char">59.1</td><td char="." align="char">11.4</td><td char="." align="char">59.1</td><td char="." align="char">40.9</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left" rowspan="2">Turkey</td><td align="left">Children with drug-responsive epilepsy</td><td char="." align="char">83</td><td align="left">26.5</td><td char="." align="char">45.8</td><td char="." align="char">27.7</td><td char="." align="char">49.4</td><td char="." align="char">50.6</td></tr><tr><td align="left">Children with drug-resistant epilepsy</td><td char="." align="char">69</td><td align="left">24.6</td><td char="." align="char">43.5</td><td char="." align="char">31.9</td><td char="." align="char">46.4</td><td char="." align="char">53.6</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR111">111</xref>]</td><td align="left">Turkey</td><td align="left">Patients receiving fentanyl for spinal anesthesia</td><td char="." align="char">83</td><td align="left">28.9</td><td char="." align="char">54.2</td><td char="." align="char">16.9</td><td char="." align="char">56.0</td><td char="." align="char">44.0</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR112">112</xref>]</td><td align="left" rowspan="2">Turkey</td><td align="left">Patients with normal CAG</td><td char="." align="char">85</td><td align="left">27.1</td><td char="." align="char">41.2</td><td char="." align="char">31.8</td><td char="." align="char">47.6</td><td char="." align="char">52.4</td></tr><tr><td align="left">Patients with CAD found on CAG</td><td char="." align="char">113</td><td align="left">27.4</td><td char="." align="char">48.7</td><td char="." align="char">23.9</td><td char="." align="char">51.8</td><td char="." align="char">48.2</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR113">113</xref>]</td><td align="left" rowspan="2">Turkey</td><td align="left">Healthy male volunteers</td><td char="." align="char">102</td><td align="left">26.5</td><td char="." align="char">49.0</td><td char="." align="char">24.5</td><td char="." align="char">51.0</td><td char="." align="char">49.0</td></tr><tr><td align="left">Male individuals with primary infertility</td><td char="." align="char">192</td><td align="left">27.6</td><td char="." align="char">57.3</td><td char="." align="char">15.1</td><td char="." align="char">56.3</td><td char="." align="char">43.7</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR114">114</xref>]</td><td align="left" rowspan="2">Turkey</td><td align="left">Healthy volunteers</td><td char="." align="char">130</td><td align="left">25.4</td><td char="." align="char">44.6</td><td char="." align="char">30.0</td><td char="." align="char">47.7</td><td char="." align="char">52.3</td></tr><tr><td align="left">Patients with familial Mediterranean fever</td><td char="." align="char">142</td><td align="left">16.9</td><td char="." align="char">59.9</td><td char="." align="char">23.2</td><td char="." align="char">46.8</td><td char="." align="char">53.2</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR115">115</xref>]</td><td align="left" rowspan="2">Turkey</td><td align="left">Healthy volunteers</td><td char="." align="char">250</td><td align="left">27.2</td><td char="." align="char">42.4</td><td char="." align="char">30.4</td><td char="." align="char">48.4</td><td char="." align="char">51.6</td></tr><tr><td align="left">Patients with familial Mediterranean fever</td><td char="." align="char">309</td><td align="left">20.4</td><td char="." align="char">55.3</td><td char="." align="char">24.3</td><td char="." align="char">48.1</td><td char="." align="char">51.9</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR116">116</xref>]</td><td align="left">Turkey</td><td align="left">Patients with familial Mediterranean fever</td><td char="." align="char">41</td><td align="left">3.7</td><td char="." align="char">54.2</td><td char="." align="char">43.4</td><td char="." align="char">29.2</td><td char="." align="char">70.8</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR117">117</xref>]</td><td align="left">Turkey</td><td align="left">Renal transplant recipients taking tacrolimus</td><td char="." align="char">92</td><td align="left">30.4</td><td char="." align="char">47.8</td><td char="." align="char">21.7</td><td char="." align="char">54.3</td><td char="." align="char">45.7</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR118">118</xref>]</td><td align="left" rowspan="2">Turkey</td><td align="left">Renal transplant recipients taking cyclosporine who did not develop gingival hyperplasia</td><td char="." align="char">114</td><td align="left">27.2</td><td char="." align="char">44.7</td><td char="." align="char">28.1</td><td char="." align="char">49.6</td><td char="." align="char">50.4</td></tr><tr><td align="left">Renal transplant recipients taking cyclosporine who developed gingival hyperplasia</td><td char="." align="char">40</td><td align="left">32.5</td><td char="." align="char">37.5</td><td char="." align="char">30.0</td><td char="." align="char">51.3</td><td char="." align="char">48.7</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR119">119</xref>]</td><td align="left" rowspan="2">Turkey</td><td align="left">Patients taking clozapine who did not develop agranulocytosis</td><td char="." align="char">91</td><td align="left">29.7</td><td char="." align="char">53.8</td><td char="." align="char">16.5</td><td char="." align="char">56.6</td><td char="." align="char">43.4</td></tr><tr><td align="left">Patients taking clozapine who developed agranulocytosis</td><td char="." align="char">10</td><td align="left">20.0</td><td char="." align="char">60.0</td><td char="." align="char">20.0</td><td char="." align="char">50.0</td><td char="." align="char">50.0</td></tr><tr><td align="left">[<xref ref-type="bibr" rid="CR120">120</xref>]</td><td align="left">Turkey</td><td align="left">Patients with non-small-cell lung cancer</td><td char="." align="char">79</td><td align="left">24.1</td><td char="." align="char">62.0</td><td char="." align="char">13.9</td><td char="." align="char">55.1</td><td char="." align="char">44.9</td></tr><tr><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR121">121</xref>]</td><td align="left" rowspan="2">Turkey</td><td align="left">Healthy volunteers</td><td char="." align="char">150</td><td align="left" colspan="3">NR</td><td char="." align="char">52.3</td><td char="." align="char">47.7</td></tr><tr><td align="left">Patients with colorectal cancer</td><td char="." align="char">103</td><td align="left" colspan="3">NR</td><td char="." align="char">61.2</td><td char="." align="char">38.8</td></tr></tbody></table><table-wrap-foot><p>
<italic>ACS</italic> acute coronary syndrome, <italic>ALL</italic> acute lymphoblastic leukemia, <italic>AML</italic> acute myeloid leukemia, <italic>CAD</italic> coronary artery disease, <italic>CAG</italic> coronary angiography, <italic>CBZ</italic> carbamazepine, <italic>CML</italic> chronic myeloid leukemia, <italic>MACE</italic> major adverse cardiac event, <italic>NA</italic> not assessed, <italic>NR</italic> not reported, <italic>PCI</italic> percutaneous coronary intervention, <italic>PHT</italic> phenytoin, <italic>RA</italic> rheumatoid arthritis</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec10"><title>CYP2C9</title><p id="Par21">CYP2C9 accounts for 70&#x02013;90% of phenytoin metabolism [<xref ref-type="bibr" rid="CR122">122</xref>], with (<italic>S</italic>)-5-(<italic>p</italic>-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) being the major resultant metabolite [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Although up to 60 different CYP2C9 haplotypes have been identified, <italic>CYP2C9*2</italic> and <italic>*3</italic> are the two most common allelic variants [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. Both variants exhibit reduced functional activity, with losses of 29 and 94% enzymatic activity reported for <italic>CYP2C9*2</italic> and <italic>*3</italic>, respectively, when compared with the wild-type genotype [<xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]. Three of the included studies investigated <italic>CYP2C9</italic> genotypes [<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par22">Aynacioglu et al. [<xref ref-type="bibr" rid="CR42">42</xref>] genotyped all outpatients and healthy volunteers for CYP2C9, and phenotyped phenytoin through assessment of serum phenytoin and p-HPPH concentrations in a subset of 101 of the Turkish healthy volunteers. Twelve hours following a single dose of phenytoin, serum phenytoin concentrations differed significantly across groups with 0, 1, and 2 loss of function mutations (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Study results indicated serum phenytoin concentration in the <italic>CYP2C9*1/*1</italic> wild-type genotype group was significantly lower when compared with <italic>CYP2C9*1/*2</italic>, <italic>CYP2C9*1/*3</italic>, and <italic>CYP2C9*2/*2</italic> genotype groups, with the difference in means being &#x02212;1.36&#x000a0;mg/L (<italic>p</italic>&#x000a0;=&#x000a0;0.009), &#x02212;1.49&#x000a0;mg/L (<italic>p</italic>&#x000a0;=&#x000a0;0.001), and &#x02212;2.42&#x000a0;mg/L (<italic>p</italic>&#x000a0;=&#x000a0;0.02), respectively. Accordingly, results also indicated the ratio of serum p-HPPH-to-phenytoin concentration of the <italic>CYP2C9*1/*1</italic> wild-type genotype group was significantly higher than that of <italic>CYP2C9*1/*2</italic>, <italic>CYP2C9*1/*3</italic>, and <italic>CYP2C9*2/*2</italic> genotype groups, with the difference in means being 0.17 (<italic>p</italic>&#x000a0;=&#x000a0;0.002), 0.22 (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001), and 0.29 (<italic>p</italic>&#x000a0;=&#x000a0;0.006), respectively. Differences between wild-type and <italic>CYP2C9*3/*3</italic> genotypes were not compared statistically, as the latter was present in only one individual.</p><p id="Par23">It was identified that data from the 96 healthy Turkish volunteers in the study conducted by Kerb et al. [<xref ref-type="bibr" rid="CR43">43</xref>] were derived from the 101 volunteers of the Aynacioglu et al. study [<xref ref-type="bibr" rid="CR42">42</xref>]. Thus, the results regarding influence of <italic>CYP2C9</italic> genotype on measured phenytoin concentrations and the p-HPPH-to-phenytoin ratio are reflected in the aforementioned results [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Using these data in a multiple linear regression analysis, Kerb et al. determined that the number of polymorphic <italic>CYP2C9</italic> alleles accounted for 14.1% of variability in phenytoin serum concentrations [<xref ref-type="bibr" rid="CR43">43</xref>]. The final regression equation, which also included the number of <italic>MDR1</italic> C3435T alleles, had an <italic>r</italic>
<sup>2</sup>&#x000a0;=&#x000a0;0.154 (<italic>p</italic>&#x000a0;=&#x000a0;0.0002).</p><p id="Par24">Ozkaynakci et al. [<xref ref-type="bibr" rid="CR44">44</xref>] reported data for 11 different combinations of <italic>CYP2C9</italic> and <italic>CYP2C19</italic> genotypes; therefore, the independent impact of the CYP2C9 genotype on serum phenytoin concentrations was difficult to discern. When compared with the <italic>CYP2C9</italic> and <italic>CYP2C19</italic> wild-type genotype group, <italic>CYP2C9*1/*3</italic>, <italic>CYP2C19*2/*3</italic> was the only genotype group with a serum phenytoin trough that was significantly different, with a mean concentration that was 20.47&#x000a0;mg/L higher than the wild-type genotype group (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). The mean serum phenytoin trough of the <italic>CYP2C9*1/*3, CYP2C19*2/*3</italic> genotype group was also significantly higher than several other genotype groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Clinical outcomes associated with <italic>CYP2C9</italic> polymorphisms were not reported and therefore could not be assessed.</p></sec><sec id="Sec11"><title>CYP2C19</title><p id="Par25">CYP2C19 accounts for 10&#x02013;30% of phenytoin metabolism, with greater metabolic contributions as CYP2C9 becomes saturated [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR127">127</xref>]. CYP2C19 primarily forms the (<italic>R</italic>)-p-HPPH metabolite [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Up to 35 different CYP2C19 haplotypes have been identified, of which <italic>CYP2C19*2</italic> and <italic>*3</italic> are the two most common null alleles; presence of two null alleles results in a non-functional CYP2C19 enzyme [<xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR125">125</xref>]. A third haplotype, <italic>CYP2C19*17</italic>, results in increased expression and activity of the enzyme [<xref ref-type="bibr" rid="CR125">125</xref>]; however, this haplotype was not assessed in the included studies. Two of the included studies investigated <italic>CYP2C19</italic> genotypes [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par26">In the study conducted by Kerb et al. [<xref ref-type="bibr" rid="CR43">43</xref>], the <italic>CYP2C19</italic> genotype did not significantly affect serum phenytoin concentration (<italic>p</italic>&#x000a0;=&#x000a0;0.52) or p-HPPH-to-phenytoin ratio (<italic>p</italic> value not reported). As with CYP2C9, as a result of Ozkaynakci et al. [<xref ref-type="bibr" rid="CR44">44</xref>] reporting the data for 11 different <italic>CYP2C9</italic> and <italic>CYP2C19</italic> genotype groups, it is difficult to distinguish the independent impact of <italic>CYP2C19</italic> genotype on serum phenytoin concentrations; therefore, no inferences can be made. As with CYP2C9, clinical outcomes were not reported and therefore could not be assessed.</p></sec><sec id="Sec12"><title>MDR1 (ABCB1) C3435T</title><p id="Par27">The <italic>MDR1</italic> (<italic>ABCB1</italic>) gene encodes for human P-glycoprotein, an efflux transporter of which phenytoin is a substrate [<xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR129">129</xref>]. The <italic>MDR1</italic> C3435T polymorphism is a silent mutation that decreases transporter expression and alters substrate specificity [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]; therefore, it has the potential to affect substrate absorption and tissue distribution. The resultant impact of this polymorphism on pharmacokinetic and pharmacodynamic outcomes of phenytoin therapy is unclear [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR132">132</xref>]. Three of the included studies investigated the <italic>MDR1</italic> C3435T polymorphism [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par28">Kerb et al. [<xref ref-type="bibr" rid="CR43">43</xref>] identified that the <italic>MDR1</italic> C3435T genotype did not significantly impact serum phenytoin concentration overall (<italic>p</italic>&#x000a0;=&#x000a0;0.064), and the number of <italic>MDR1 T</italic> alleles accounted for only 1.3% of the variability in serum phenytoin concentrations in their multiple regression analysis. As discussed previously, the final regression equation had an <italic>r</italic>
<sup>2</sup>&#x000a0;=&#x000a0;0.154 (<italic>p</italic>&#x000a0;=&#x000a0;0.0002). When serum phenytoin concentrations were divided into quartiles (25th percentile: &#x0003c;3.79&#x000a0;mg/L, interquartile range: 3.79&#x02013;5.79&#x000a0;mg/L, 75th percentile: &#x0003e;5.79&#x000a0;mg/L), the frequency distribution of MDR1 genotype indicated that the <italic>MDR1 CC</italic> genotype was more frequent in the 25th percentile group (<italic>p</italic>&#x000a0;&#x02264;&#x000a0;0.001, <italic>&#x003c7;</italic>
<sup>2</sup> test). Moreover, while the presence of the <italic>MDR1 TT</italic> genotype reportedly had significant influence on p-HPPH-to-phenytoin ratio (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.026), absolute values were not provided and there was considerable overlap in the depicted frequency distribution; therefore, clinical significance of this association cannot be inferred.</p><p id="Par29">Alhazzani et al. [<xref ref-type="bibr" rid="CR45">45</xref>] identified significant differences between the <italic>CC</italic>, <italic>CT</italic>, and <italic>TT</italic> genotypes (classified as extensive, intermediate, or poor metabolizers, respectively) for the pharmacokinetic parameters of maximum plasma concentration (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01), area under the plasma concentration&#x02013;time curve from 0 to 12&#x000a0;h post-dose (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01), half-life (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01), and clearance (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01) using one-way analysis of variance. However, post-hoc analyses were not performed to identify which genotypes differed significantly for these parameters. There was no difference between genotype groups for the parameter of time to maximum plasma concentration (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05). The reported values for each genotype are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Moreover, a significant association between the <italic>MDR1</italic> C3435T genotype and phenytoin response was reported. Non-responders (i.e., phenytoin-resistant patients) had a higher frequency of the <italic>T</italic> allele (<italic>&#x003c7;</italic>
<sup>2</sup>&#x000a0;=&#x000a0;9.76, <italic>p</italic>&#x000a0;=&#x000a0;0.0017) and, accordingly, the <italic>CT</italic> or <italic>TT</italic> genotypes (<italic>&#x003c7;</italic>
<sup>2</sup>&#x000a0;=&#x000a0;4.37, <italic>p</italic>&#x000a0;=&#x000a0;0.036). The odds ratio (OR) calculated from the identified frequencies was significant for the allelic frequency [OR 3.14; 95% confidence interval (CI) 1.42&#x02013;7.05], but not for the genotypic (OR 3.69; 95% CI 0.90&#x02013;5.81).</p><p id="Par30">Ebid et al. [<xref ref-type="bibr" rid="CR46">46</xref>] did not identify a significant association between drug resistance or responsiveness and phenytoin concentrations overall, but reported associations between the <italic>MDR1 CC</italic> genotype and the likelihood of drug-resistant patients having serum phenytoin trough concentrations below or in the lower half of therapeutic range at the 3- and 6-month evaluations. Whether the <italic>MDR1</italic> C3435T genotype influences the efficacy and toxicity of phenytoin in epilepsy management was also explored. Overall, patients who were drug resistant (i.e., had seizure recurrence in the preceding 3&#x000a0;months) were more likely to have the <italic>MDR1 CC</italic> genotype than the <italic>MDR1 TT</italic> genotype when compared with patients responsive to therapy (55.5 vs. 13.5%, <italic>&#x003c7;</italic>
<sup>2</sup>&#x000a0;=&#x000a0;24.99; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001). Moreover, as would be expected, within the drug-resistant group, seizures occurred at higher frequency in patients with serum phenytoin trough &#x0003c;10&#x000a0;mg/L, with average seizure frequencies of 4.4 and 3.7 at 3 and 6&#x000a0;months, respectively (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001).</p></sec><sec id="Sec13"><title>Genotypic and Allelic Frequencies Within the MENA Region</title><p id="Par31">Variant MAF of <italic>CYP2C9</italic>, <italic>CYP2C19</italic>, and <italic>MDR1 (ABCB1)</italic> C3435T have been investigated in a variety of settings and study populations across the MENA region. Studies from 11 different countries were identified for both <italic>CYP2C9</italic> and <italic>CYP2C19</italic>, and seven countries for <italic>MDR1 (ABCB1)</italic> C3435T; study populations and computed genotypic and allelic frequencies for each polymorphism are summarized in Tables&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, <xref rid="Tab4" ref-type="table">4</xref>, and <xref rid="Tab5" ref-type="table">5</xref>, respectively. Overall, there was appreciable variability in MAF both between and within countries of the MENA region for each of <italic>CYP2C9</italic>, <italic>CYP2C19</italic>, and <italic>MDR1 (ABCB1)</italic> C3435T. For example, in studies assessing subjects of Turkish origin, the reported <italic>CYP2C19*3</italic> MAF ranged from 0 to 10.3% [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR87">87</xref>&#x02013;<xref ref-type="bibr" rid="CR89">89</xref>].</p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p id="Par32">The purpose of this systematic review was to evaluate the role of genetic polymorphisms on phenytoin pharmacokinetics and clinical outcomes specifically in populations originating from the MENA region, and to characterize assessed polymorphism variant MAF within the region. Recognizing and understanding factors that contribute to interpatient variability in pharmacokinetics, pharmacodynamics, and associated clinical outcomes is essential to providing patient-individualized pharmacotherapy and disease management. In the management of epilepsy and seizure disorders, the significant role of genetic polymorphisms as one such factor has received increasing recognition, with phenytoin being an antiepileptic drug of particular interest, owing to its unique pharmacokinetic and pharmacodynamic profile [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR133">133</xref>, <xref ref-type="bibr" rid="CR134">134</xref>]</p><sec id="Sec15"><title>CYP2C9</title><p id="Par33">Findings of the studies included in this review indicate that the reduced functional capacity of CYP2C9 enzymes with <italic>CYP2C9*2</italic> and <italic>CYP2C9*3</italic> variant alleles results in significantly higher serum phenytoin concentrations [<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>]. This difference was significant after only a single dose of phenytoin in healthy volunteers included in the studies by Aynacioglu et al. [<xref ref-type="bibr" rid="CR42">42</xref>] and Kerb et al. [<xref ref-type="bibr" rid="CR43">43</xref>]. Although the absolute difference between the wild-type genotype and those with one or two reduced function alleles was only in the range of 1.32&#x02013;2.42&#x000a0;mg/L, owing to the reduced functional capacity of enzymes with variant alleles, it is reasonable to surmise that the absolute difference in phenytoin concentrations would likely be of clinical significance with repeat dosing [<xref ref-type="bibr" rid="CR5">5</xref>]. This notion is supported by an in-vitro study of <italic>CYP2C9</italic> polymorphisms, wherein <italic>*2</italic> and <italic>*3</italic> allelic variants decreased maximal velocity by 29 and 79%, respectively, and while the <italic>*2</italic> variant did not affect the Michaelis constant, the <italic>*3</italic> variant increased it fourfold [<xref ref-type="bibr" rid="CR126">126</xref>].</p><p id="Par34">Ozkaynakci et al. [<xref ref-type="bibr" rid="CR44">44</xref>] reported a statistically significant difference between the wild-type and <italic>CYP2C9*1/*3, CYP2C19*2/*3</italic> genotype groups. However, five of the 11 reported genotype groups had frequencies of only 0.98&#x02013;2.94%, which likely limited the power of the study to detect differences between the wild-type and other genotype groups. Moreover, patients were required to have been taking phenytoin for only 7&#x000a0;days. Therefore, it is possible that some patients were not yet at steady state when phenytoin trough concentrations were drawn, and that absolute differences in concentrations would be statistically and/or clinically significant over time [<xref ref-type="bibr" rid="CR5">5</xref>]. This is especially noteworthy in those with <italic>CYP2C9*2</italic> or <italic>*3</italic> alleles, in whom reduced functional capacity may significantly prolong the time necessary to achieve steady-state concentrations [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. As well, patients were not on a fixed dose of phenytoin; therefore, knowing the mean dose within each genotype group or having a serum concentration adjusted for mean dose in each genotype group would allow for assessment of this as a potential confounder. Although the impact of polytherapy was explored, the study was underpowered to appropriately assess this outcome. Thus, these results do not provide a clear demonstration of the impact of <italic>CYP2C9*2</italic> and *<italic>3</italic> allelic variants on phenytoin pharmacokinetics.</p><p id="Par35">The impact of <italic>CYP2C9</italic> variants have been more clearly demonstrated in studies conducted in non-MENA populations. In a cohort of Japanese pediatric patients, when controlling for <italic>CYP2C19</italic> polymorphisms, patients with the <italic>CYP2C9*1/*3</italic> genotype required phenytoin maintenance doses that were 37.3% lower than those with the wild-type genotype to achieve target concentrations of 15&#x02013;20&#x000a0;mg/L [<xref ref-type="bibr" rid="CR10">10</xref>]. Similarly, in a sample of Dutch patients, those with at least one <italic>CYP2C9*2</italic> or <italic>*3</italic> allele required phenytoin maintenance doses that were 37% lower to achieve target concentrations of 10&#x02013;20&#x000a0;mg/L [<xref ref-type="bibr" rid="CR24">24</xref>]. A study of patients originating from India indicated that those with the <italic>CYP2C9*1/*3</italic> genotype were more likely than the wild-type genotype to have serum phenytoin concentrations &#x0003e;20&#x000a0;mg/L (OR 4.8; 95% CI 1.89&#x02013;12.17; <italic>p</italic> 0.001), despite receiving comparable maintenance doses of phenytoin (5.4 vs. 5.1&#x000a0;mg/kg/day; <italic>p</italic>&#x000a0;=&#x000a0;0.16) [<xref ref-type="bibr" rid="CR133">133</xref>]. In addition to the impact of <italic>CYP2C9</italic> polymorphisms on phenytoin pharmacokinetics in non-MENA populations, it also had an effect on phenytoin safety outcomes. A case-control study of Thai patients demonstrated that, when on comparable maintenance phenytoin doses, patients with the <italic>CYP2C9*1/*3</italic> genotype were more likely to develop phenytoin-induced severe cutaneous adverse reactions (i.e., Stevens&#x02013;Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms) within 12&#x000a0;weeks of initiating therapy than those with the wild-type genotype (OR 14.52; 95% CI 1.18&#x02013;&#x0221e;; <italic>p</italic> 0.044) [<xref ref-type="bibr" rid="CR134">134</xref>]. This association is supported by findings of a meta-analysis conducted in Asian populations, wherein the <italic>CYP2C9*3</italic> allele was associated with an increased risk of phenytoin-induced severe cutaneous reactions (OR 11.0; 95% CI 6.2&#x02013;18.0; <italic>p</italic> &#x0003c; 0.00001) [<xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, in a case-control study of Tamilian patients, when adjusting for phenytoin maintenance dose, patients with the <italic>CYP2C9*1/*3</italic> genotype were significantly more likely to experience phenytoin-induced neurological toxicity (e.g., ataxia, slurred speech, lethargy, nystagmus) when compared with wild-type genotype (adjusted OR 15.3; 95% CI 5.8&#x02013;40.3; <italic>p</italic> 0.0001) [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par36">Ultimately, the significant impact of <italic>CYP2C9*2</italic> and <italic>*3</italic> allelic variants on phenytoin pharmacokinetics and risk of adverse effects when standard doses are administered has led to development of genotype-specific recommendations. It is suggested that initial doses of phenytoin be reduced by 25% in patients with one variant allele (i.e., <italic>CYP2C9*1/*2</italic> or <italic>*1/*3</italic>) and by 50% in patients with two variant alleles (i.e., <italic>CYP2C9*2/*2, *2/*3</italic> or <italic>*3/*3</italic>) [<xref ref-type="bibr" rid="CR8">8</xref>].</p></sec><sec id="Sec16"><title>CYP2C19</title><p id="Par37">Results of this review suggest that <italic>CYP1C19*2</italic> and <italic>*3</italic> allelic variants, on their own, did not significantly impact the pharmacokinetics of phenytoin. In the single-dose study by Kerb et al. [<xref ref-type="bibr" rid="CR43">43</xref>], using the same rationale as discussed with CYP2C9, although <italic>CYP2C19*1/*2</italic> and <italic>*2/*2</italic> genotypes were not associated with significantly different phenytoin serum concentrations, owing to the non-functional nature of <italic>*2</italic> alleles, it is possible that statistically and clinically differences would arise after repeat dosing [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par38">For results regarding CYP2C19 reported by Ozkaynakci et al. [<xref ref-type="bibr" rid="CR44">44</xref>], previously discussed limitations affecting interpretation of results regarding CYP2C9 also apply. Both studies included in this review were likely underpowered to assess the impact of <italic>CYP2C19</italic> polymorphisms specifically. Moreover, because CYP2C19 accounts for only 10&#x02013;30% of phenytoin metabolism [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR127">127</xref>], decreased or loss of functional capacity may be less likely to significantly affect phenytoin serum concentrations when compared with <italic>CYP2C9</italic> allelic variants with reduced function.</p><p id="Par39">Evidence from studies conducted in non-MENA populations suggest that CYP2C19 allelic variants may significantly impact pharmacokinetics of phenytoin. In the previously described Japanese cohort, those with <italic>CYP2C9</italic> wild-type genotype and one variant <italic>CYP2C19</italic> allele (i.e., <italic>CYP2C19*1/*2</italic> or <italic>*1/*3</italic>) required phenytoin doses 13.1% lower than patients with wild-type genotypes of both <italic>CYP2C9</italic> and <italic>CYP2C19</italic> to achieve target concentrations (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01), while those with two variant <italic>CYP2C19</italic> alleles (i.e., <italic>CYP2C19*2/*2</italic>, <italic>*2/*3, or *3/*3)</italic> required doses 28.1% lower (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) [<xref ref-type="bibr" rid="CR10">10</xref>]. Regarding clinical outcomes, in the study conducted in Tamilian patients, when adjusting for maintenance dose, patients with <italic>CYP2C19*2/*2</italic> genotype were significantly more likely to experience phenytoin-induced neurological toxicity when compared with wild-type genotype (adjusted OR 3.0; 95% CI 1.3&#x02013;7.0; <italic>p</italic> 0.01) [<xref ref-type="bibr" rid="CR22">22</xref>]. Evidence from studies assessing both <italic>CYP2C9</italic> and <italic>CYP2C19</italic> genotypes suggest additive impact on phenytoin concentrations when variant genotypes of both enzymes are present [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Although official guidelines have not been developed for dosage adjustments in patients with <italic>CYP2C19</italic> allelic variants, recommendations for both pediatric and adult patients have been suggested based on the combination of both <italic>CYP2C9</italic> and <italic>CYP2C19</italic> genotypes [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec17"><title>MDR1 (ABCB1) C3435T</title><p id="Par40">The reported impact of the <italic>MDR1</italic> C3435T genotype on phenytoin pharmacokinetics in this review was inconsistent, and results in all three studies [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>] may have been confounded because of aforementioned factors such as concomitant medications, comorbid conditions, and serum albumin levels, among other patient-specific factors.</p><p id="Par41">Kerb et al. [<xref ref-type="bibr" rid="CR43">43</xref>] reported no significant association between <italic>MDR1</italic> genotype and serum phenytoin concentrations overall. Although post-hoc analysis identified a significant association between the <italic>MDR1 CC</italic> genotype and serum phenytoin concentrations in the 25th percentile, the association is likely of limited clinical significance because of the narrow concentration range defined by the three classes of low, medium, and high. Unlike CYP2C9 and CYP2C19, transporters encoded by <italic>MDR1</italic> are not involved in phenytoin metabolism; therefore, it is unclear whether repeat dosing over time would significantly impact the observed degree of difference in phenytoin serum concentrations between genotype groups. Moreover, although presence of <italic>MDR1 T</italic> alleles accounted for 1.3% of variability in phenytoin serum concentrations, the clinical relevance of this is questionable, especially considering the final regression equation could account for only 15.4% of observed variability [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p id="Par42">In contrast, results reported by Alhazzani et al. [<xref ref-type="bibr" rid="CR45">45</xref>] indicate all pharmacokinetic parameters, with the exception of time to maximum plasma concentration, were significantly affected by the <italic>MDR1</italic> C3435T genotype. In the absence of post-hoc analyses of the one-way analysis of variance, which genotypes significantly differed for these parameters cannot be confirmed; however, the results trend toward the <italic>MDR1 CC</italic> genotype group being different. Of note, the classification of extensive, intermediate, and poor metabolizer to describe the <italic>MDR1</italic> C3435T genotype is misleading, as proteins encoded by <italic>MDR1</italic> are involved in substrate absorption and distribution, not metabolism [<xref ref-type="bibr" rid="CR129">129</xref>&#x02013;<xref ref-type="bibr" rid="CR131">131</xref>]. The trend of increased maximum plasma concentration, area under the plasma concentration&#x02013;time curve from 0 to 12 h post-dose, half-life, and clearance in subjects with one or more <italic>T</italic> alleles holds face validity, as this variant is associated with lower levels of transporter expression [<xref ref-type="bibr" rid="CR130">130</xref>], which, at the level of the intestine, would result in less phenytoin being effluxed from systemic circulation back into the intestinal lumen. The distributions of responders and non-responders across the extensive, intermediate, and poor metabolizer categories were not reported; therefore, associations between the <italic>MDR1</italic> C3435T genotype, phenytoin pharmacokinetics, and resultant clinical outcomes could not be assessed.</p><p id="Par43">The clinical significance of the association between serum phenytoin level and <italic>MDR1</italic> C3435T genotype reported by Ebid et al. [<xref ref-type="bibr" rid="CR46">46</xref>] is unclear. Specifically, at the 3-month evaluation, there was no significant association between phenytoin responsiveness and serum concentration overall, while at the 6-month evaluation, a &#x02018;higher&#x02019; concentration in the drug-responsive group was not defined and whether or not weight adjusting the doses mitigated reported differences was not explored.</p><p id="Par44">Reported associations between the <italic>MDR1</italic> C3435T genotype and drug resistance reported in this review are conflicting [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Historically, associations between drug-resistant epilepsy and overexpression of transporters encoded by <italic>MDR1</italic> have been reported [<xref ref-type="bibr" rid="CR135">135</xref>&#x02013;<xref ref-type="bibr" rid="CR137">137</xref>]. Despite this, several limitations must be considered when interpreting the clinical outcomes reported by Ebid et al. [<xref ref-type="bibr" rid="CR46">46</xref>]. Foremost, distribution of seizure type within the drug-responsive and drug-resistant groups was not reported, nor adjusted for in the results. This is notable, as there is evidence to suggest phenytoin may aggravate generalized seizures [<xref ref-type="bibr" rid="CR3">3</xref>]. Additional potential confounders, such as baseline seizure control and concomitant antiepileptic drugs, were also not adjusted for. It is unclear if appropriate corrections were made for multiple statistical analyses; thus, it is possible that identified associations were the result of chance.</p><p id="Par45">The association of <italic>MDR1</italic> C3435T genetic polymorphisms and drug-resistant epilepsy in general (as opposed to phenytoin specifically) was assessed within Iranian patients [<xref ref-type="bibr" rid="CR33">33</xref>]. The <italic>MDR1&#x000a0;CC</italic> wild-type genotype was significantly more frequent in drug-resistant patients, and associations were also made with adult age and female sex; however, the latter two associations may have resulted from performing multiple statistical analyses. The investigators attempted to address confounders such as baseline etiology and seizure type through univariate analyses; however, because baseline characteristics were so different between study groups, residual confounding likely remained [<xref ref-type="bibr" rid="CR33">33</xref>]. Two studies conducted in Turkish patients with seizure disorders did not find a significant association between the <italic>MDR1</italic> C3435T genotype and drug resistance [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. More recently, a meta-analysis of studies conducted in Asian, Caucasian (under which populations originating from the MENA region were classified), and Indian populations investigated the role of <italic>MDR1</italic> gene haplotypes in antiepileptic drug response [<xref ref-type="bibr" rid="CR132">132</xref>]. Initial results indicated that the presence of the T variant of <italic>MDR1</italic> C3435T may be associated with lower rates of drug resistance. Once corrected for multiple statistical analyses, there was no significant association overall, but a significant association remained in Caucasian patients (<italic>T</italic> vs. <italic>C</italic> allele, OR 0.83; 95% CI 0.71&#x02013;0.96; <italic>p</italic> = 0.01) [<xref ref-type="bibr" rid="CR132">132</xref>]. One hypothesis regarding inconsistency in positive associations found between <italic>MDR1</italic> genotypes and responsiveness to antiepileptic drugs is that the gene falls within a significant block of high linkage disequilibrium [<xref ref-type="bibr" rid="CR138">138</xref>]. Therefore, it is possible that the associations identified are not the result of the <italic>MDR1</italic> polymorphism itself, but to an alternative gene within the linkage disequilibrium block [<xref ref-type="bibr" rid="CR138">138</xref>].</p></sec><sec id="Sec18"><title>Genotypic and Allelic Frequencies Within the MENA Region</title><p id="Par46">Variability in genotypic and allelic frequencies of <italic>CYP2C9</italic>, <italic>CYP2C19</italic>, and <italic>MDR1</italic> C3435T both between and within the MENA countries for which data were identified was not unexpected. Key factors contributing to this variability were likely small sample sizes and selective patient populations in whom many of the studies were conducted. The allelic frequencies of <italic>CYP2C9*2</italic> and <italic>*3</italic>, as well as <italic>CYP2C19*2</italic> and <italic>*3</italic> were comparable to those reported for Middle Eastern populations [<xref ref-type="bibr" rid="CR139">139</xref>, <xref ref-type="bibr" rid="CR140">140</xref>]. Similar population data for the <italic>MDR1</italic> C3435T polymorphism were not available for comparison, nor were comparative data specific to North Africa populations.</p><p id="Par47">Ethnicity significantly affects distributions of variants [<xref ref-type="bibr" rid="CR124">124</xref>] and contributes to differences in MAF reported for populations outside of the MENA region for each of <italic>CYP2C9</italic> [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR139">139</xref>], <italic>CYP2C19</italic> [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR140">140</xref>], and <italic>MDR1</italic> C3435T [<xref ref-type="bibr" rid="CR132">132</xref>, <xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR142">142</xref>]. This emphasizes the importance of population-specific studies assessing genetic polymorphisms.</p></sec><sec id="Sec19"><title>Limitations</title><p id="Par48">This review has several limitations that must be considered when interpreting the results. Foremost, in the primary analysis, only three different countries within the MENA region were represented by study populations, with three of five studies being in subjects of Turkish origin. The genotypic diversity across MENA countries as well as the small sample size of the included studies, therefore limit the generalizability of this review. Moreover, only three of the five studies were conducted in patients with seizure disorder, of which only one assessed clinical outcomes, thereby limiting ability to make clinical inferences. The two healthy volunteer studies (which used data from the same subjects) were based on a single dose of phenytoin; therefore, they did not reflect the potential impact of genetic polymorphisms on the steady-state pharmacokinetics of phenytoin or the influence of the non-linear capacity-limited metabolism of phenytoin. Furthermore, all five studies had poor methodological quality and were likely not powered to compare differences between genotypes and alleles of relatively low frequencies. Regarding the review of genotypic and allelic frequencies, the small select study populations and resultant variability in frequency estimates limit generalizability.</p></sec><sec id="Sec20"><title>Future Directions</title><p id="Par49">Identified limitations of this review highlight the need for future studies to investigate the impact of genetic polymorphisms on the pharmacokinetics of phenytoin and associated clinical outcomes, specifically in patients with epilepsy and seizure disorders. Although the impacts of <italic>CYP2C9*2</italic> and <italic>*3</italic> allelic variants on phenytoin metabolism and the risk of adverse effects have been recognized and dosage modification guidelines&#x000a0;developed&#x000a0;[<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], the potential impacts of <italic>CYP2C19*2</italic> and <italic>*3</italic> allelic variants have not been established and warrant further investigation. Moreover, owing to the limitations of individual studies, the association between the <italic>MDR1</italic> C3435T genotype and drug-resistant epilepsy as well as phenytoin pharmacokinetics remains to be elucidated. To address these questions, future studies must be appropriately powered to assess differences between genotypes of low frequencies, and account for known confounding factors. Furthermore, studies should be designed to look at both pharmacokinetic and clinical outcomes once phenytoin concentrations have achieved a steady state. If possible, studies should be conducted in patient populations originating from countries of the MENA region that have not yet been assessed.</p><p id="Par50">Future research may also focus on investigating the prevalence of the <italic>HLA-B*15:02</italic> allele and its impact on the risk of phenytoin-induced severe cutaneous adverse reactions (i.e., Stevens&#x02013;Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms) in populations originating within the MENA region. The presence of this allele has been associated with an increased risk of phenytoin-induced severe cutaneous adverse reactions [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR143">143</xref>&#x02013;<xref ref-type="bibr" rid="CR145">145</xref>], resulting in pharmacogenetic guidelines recommending against the use of phenytoin in patients who are <italic>HLA-B*15:02</italic> carriers [<xref ref-type="bibr" rid="CR8">8</xref>].</p></sec></sec><sec id="Sec21" sec-type="conclusion"><title>Conclusion</title><p id="Par51">Results of this review indicate the reduced functional capacities of <italic>CYP2C9*2</italic> and <italic>*3</italic> allelic variants significantly decrease phenytoin metabolism in patients originating from the MENA region. The impacts of <italic>CYP2C19</italic> and <italic>MDR1</italic> C3435T polymorphisms on phenytoin pharmacokinetics and clinical outcomes in this population are unclear and require further investigation. Future research should focus on better understanding the impact of genetic polymorphisms on clinical outcomes associated with phenytoin therapy.</p></sec></body><back><app-group><app id="App1"><sec id="Sec22"><title>Appendix: MEDLINE search strategy</title><p>
<list list-type="order"><list-item><p id="Par54">MENA.mp.</p></list-item><list-item><p id="Par55">exp Africa, Northern/ or &#x0201c;Middle East and North Africa&#x0201d;.mp. or exp Middle East/</p></list-item><list-item><p id="Par56">Afghanistan.mp. or exp Afghanistan/</p></list-item><list-item><p id="Par57">Bahrain.mp. or exp Bahrain/</p></list-item><list-item><p id="Par58">Djibouti.mp. or exp Djibouti/</p></list-item><list-item><p id="Par59">Egypt.mp. or exp Egypt/</p></list-item><list-item><p id="Par60">Algeria.mp. or exp Algeria/</p></list-item><list-item><p id="Par61">Iran.mp. or exp Iran/</p></list-item><list-item><p id="Par62">exp Iraq/ or Iraq.mp.</p></list-item><list-item><p id="Par63">Israel.mp. or exp Israel/</p></list-item><list-item><p id="Par64">Jordan.mp. or exp Jordan/</p></list-item><list-item><p id="Par65">Kuwait.mp. or exp Kuwait/</p></list-item><list-item><p id="Par66">Lebanon.mp. or exp Lebanon/</p></list-item><list-item><p id="Par67">Libya.mp. or exp Libya/</p></list-item><list-item><p id="Par68">Morocco.mp. or exp Morocco/</p></list-item><list-item><p id="Par69">Oman.mp. or exp Oman/</p></list-item><list-item><p id="Par70">Palestine.mp.</p></list-item><list-item><p id="Par71">West Bank.mp.</p></list-item><list-item><p id="Par72">Gaza.mp.</p></list-item><list-item><p id="Par73">Qatar.mp. or exp Qatar/</p></list-item><list-item><p id="Par74">Saudi Arabia.mp. or exp Saudi Arabia/</p></list-item><list-item><p id="Par75">Somalia.mp. or exp Somalia/</p></list-item><list-item><p id="Par76">exp South Sudan/ or exp Sudan/ or Sudan.mp.</p></list-item><list-item><p id="Par77">Syria.mp. or exp Syria/</p></list-item><list-item><p id="Par78">Tunisia.mp. or exp Tunisia/</p></list-item><list-item><p id="Par79">exp Turkey/ or Turkey.mp.</p></list-item><list-item><p id="Par80">United Arab Emirates.mp. or exp United Arab Emirates/</p></list-item><list-item><p id="Par81">Yemen.mp. or exp Yemen/</p></list-item><list-item><p id="Par82">1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28</p></list-item><list-item><p id="Par83">Polymorphism.mp. or exp Polymorphism, Genetic/ or exp Polymorphism, Single Nucleotide/</p></list-item><list-item><p id="Par84">Pharmacogenetics.mp. or exp Pharmacogenetics/</p></list-item><list-item><p id="Par85">Pharmacogenomics.mp.</p></list-item><list-item><p id="Par86">cytochrome p450.mp. or exp Cytochrome P-450 Enzyme System/</p></list-item><list-item><p id="Par87">CYP2C9.mp. or exp Cytochrome P-450 CYP2C9/</p></list-item><list-item><p id="Par88">CYP2C19.mp. or exp Cytochrome P-450 CYP2C19/</p></list-item><list-item><p id="Par89">CYP3A4.mp. or exp Cytochrome P-450 CYP3A/</p></list-item><list-item><p id="Par90">CYP2B6.mp. or exp Cytochrome P-450 CYP2B6/</p></list-item><list-item><p id="Par91">CYP1A2.mp. or exp Cytochrome P-450 CYP1A2/</p></list-item><list-item><p id="Par92">CYP2E1.mp. or exp Cytochrome P-450 CYP2E1/</p></list-item><list-item><p id="Par93">CYP2C8.mp. or exp Cytochrome P-450 CYP2C8/</p></list-item><list-item><p id="Par94">exp Cytochrome P-450 CYP2A6/ or CYP2A6.mp.</p></list-item><list-item><p id="Par95">exp Glucuronosyltransferase/ or UGT.mp.</p></list-item><list-item><p id="Par96">UGT1A1.mp.</p></list-item><list-item><p id="Par97">UGT1A4.mp.</p></list-item><list-item><p id="Par98">UGT1A6.mp.</p></list-item><list-item><p id="Par99">UGT1A9.mp.</p></list-item><list-item><p id="Par100">P-glycoprotein.mp. or exp P-Glycoprotein/</p></list-item><list-item><p id="Par101">multi drug resistance protein.mp. or exp Multidrug Resistance-Associated Proteins/ or exp ATP-Binding Cassette Transporters/</p></list-item><list-item><p id="Par102">exp P-Glycoproteins/ or exp P-Glycoprotein/ or MDR1.mp.</p></list-item><list-item><p id="Par103">ABCB1.mp.</p></list-item><list-item><p id="Par104">30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50</p></list-item><list-item><p id="Par105">phenytoin.mp. or exp Phenytoin/</p></list-item><list-item><p id="Par106">antiepileptic.mp. or exp Anticonvulsants/</p></list-item><list-item><p id="Par107">exp Epilepsy/ or epilepsy.mp.</p></list-item><list-item><p id="Par108">52 or 53 or 54</p></list-item><list-item><p id="Par109">29 and 51 and 55</p></list-item></list>
</p></sec></app></app-group><notes notes-type="COI-statement"><title>Compliance with Ethical Standards</title><sec id="FPar2"><title>Funding</title><p id="Par52">No funding was received for the preparation of this article.</p></sec><sec id="FPar3"><title>Conflict of interest</title><p id="Par53">Ren&#x000e9;e Dagenais, Kyle John Wilby, Hazem Elewa, and Mary H.H. Ensom have no conflicts of interest directly relevant to the content of this article.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merritt</surname><given-names>HH</given-names></name><name><surname>Putnam</surname><given-names>TJ</given-names></name></person-group><article-title>Sodium diphenyl hydantoinate in the treatment of convulsive disorders</article-title><source>JAMA.</source><year>1939</year><volume>11</volume><fpage>1068</fpage><lpage>1073</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glauser</surname><given-names>T</given-names></name><name><surname>Shinnar</surname><given-names>S</given-names></name><name><surname>Gloss</surname><given-names>D</given-names></name><name><surname>Alldredge</surname><given-names>B</given-names></name><name><surname>Arya</surname><given-names>R</given-names></name><name><surname>Bainbridge</surname><given-names>J</given-names></name><etal/></person-group><article-title>Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society</article-title><source>Epilepsy Curr.</source><year>2016</year><volume>16</volume><fpage>48</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.5698/1535-7597-16.1.48</pub-id><?supplied-pmid 26900382?><pub-id pub-id-type="pmid">26900382</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glauser</surname><given-names>T</given-names></name><name><surname>Ben-Menachem</surname><given-names>E</given-names></name><name><surname>Bourgeois</surname><given-names>B</given-names></name><name><surname>Cnaan</surname><given-names>A</given-names></name><name><surname>Guerreiro</surname><given-names>C</given-names></name><name><surname>K&#x000e4;lvi&#x000e4;inen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes</article-title><source>Epilepsia.</source><year>2013</year><volume>54</volume><fpage>551</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1111/epi.12074</pub-id><?supplied-pmid 23350722?><pub-id pub-id-type="pmid">23350722</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>RJ</given-names></name><name><surname>Meldrum</surname><given-names>BS</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Katzung</surname><given-names>BG</given-names></name><name><surname>Masters</surname><given-names>SB</given-names></name><name><surname>Trevor</surname><given-names>AJ</given-names></name></person-group><article-title>Antiseizure drugs</article-title><source>Basic and clinical pharmacology</source><year>2012</year><edition>12</edition><publisher-loc>London</publisher-loc><publisher-name>The McGraw-Hill Companies, Inc.</publisher-name></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>ME</given-names></name><name><surname>Tozer</surname><given-names>TN</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Burton</surname><given-names>ME</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Schentag</surname><given-names>JJ</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name></person-group><article-title>Phenytoin</article-title><source>Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring</source><year>2006</year><edition>4</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch-Weser</surname><given-names>J</given-names></name></person-group><article-title>The serum level approach to individualization of drug dosage</article-title><source>Eur J Clin Pharmacol.</source><year>1975</year><volume>9</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/BF00613423</pub-id><?supplied-pmid 786685?><pub-id pub-id-type="pmid">786685</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Thorn CF, Whirl-Carrillo M, Leeder JS, Klein TE, Altman RB. PharmGKB summary: phenytoin pathway. Pharmacogenetics Genom. 2012. <ext-link ext-link-type="uri" xlink:href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</ext-link>. Accessed 22 Feb 2017.</mixed-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caudle</surname><given-names>KE</given-names></name><name><surname>Rettie</surname><given-names>AE</given-names></name><name><surname>Whirl-carrillo</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>LH</given-names></name><name><surname>Mintzer</surname><given-names>SE</given-names></name><name><surname>Ta</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical pharmacogenetics implementation consortium guidelines for <italic>CYP2C9</italic> and <italic>HLA-B</italic> genotype and phenytoin dosing</article-title><source>Clin Pharmacol Ther.</source><year>2014</year><volume>96</volume><fpage>542</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/clpt.2014.159</pub-id><?supplied-pmid 25099164?><pub-id pub-id-type="pmid">25099164</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swen</surname><given-names>JJ</given-names></name><name><surname>Nijenhuis</surname><given-names>M</given-names></name><name><surname>de Boer</surname><given-names>A</given-names></name><name><surname>Grandia</surname><given-names>L</given-names></name><name><surname>Maitland-van der Zee</surname><given-names>AH</given-names></name><name><surname>Mulder</surname><given-names>H</given-names></name><etal/></person-group><article-title>Pharmacogenetics: from bench to byte: an update of guidelines</article-title><source>Clin Pharmacol Ther.</source><year>2011</year><volume>89</volume><fpage>662</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1038/clpt.2011.34</pub-id><?supplied-pmid 21412232?><pub-id pub-id-type="pmid">21412232</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Miyakawa</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes</article-title><source>Ther Drug Monit.</source><year>2015</year><volume>37</volume><fpage>229</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000128</pub-id><?supplied-pmid 25162219?><pub-id pub-id-type="pmid">25162219</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Public Health Genomics Knowledge Base. Phenytoin. 2016. <ext-link ext-link-type="uri" xlink:href="https://phgkb.cdc.gov/">https://phgkb.cdc.gov/</ext-link>. Accessed 25 Feb 2017.</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">PharmGKB. Phenytoin. 2017. <ext-link ext-link-type="uri" xlink:href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</ext-link>. Accessed 25 Feb 2017.</mixed-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henn</surname><given-names>BM</given-names></name><name><surname>Botigu&#x000e9;</surname><given-names>LR</given-names></name><name><surname>Gravel</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Brisbin</surname><given-names>A</given-names></name><name><surname>Byrnes</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Genomic ancestry of North Africans supports back-to-Africa migrations</article-title><source>PLoS Genet.</source><year>2012</year><volume>8</volume><fpage>e1002397</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1002397</pub-id><?supplied-pmid 22253600?><pub-id pub-id-type="pmid">22253600</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Peter</surname><given-names>I</given-names></name><name><surname>Scott</surname><given-names>SA</given-names></name></person-group><article-title>Pharmacogenetics in Jewish populations</article-title><source>Drug Metabol Drug Interact.</source><year>2014</year><volume>29</volume><fpage>221</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1515/dmdi-2013-0069</pub-id><?supplied-pmid 24867283?><pub-id pub-id-type="pmid">24867283</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Al-Bustan</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Marafie</surname><given-names>M</given-names></name><etal/></person-group><article-title>The influence of admixture and consanguinity on population genetic diversity in Middle East</article-title><source>J Hum Genet.</source><year>2014</year><volume>59</volume><fpage>615</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1038/jhg.2014.81</pub-id><?supplied-pmid 25253659?><pub-id pub-id-type="pmid">25253659</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">NIH National Heart, Lung, and Blood Institute. Quality assessment tool for observational cohort and cross-sectional studies. 2014. <ext-link ext-link-type="uri" xlink:href="https://www.nhlbi.nih.gov/">https://www.nhlbi.nih.gov/</ext-link>. Accessed 1 Feb 2017.</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>WH</given-names></name><name><surname>Chang</surname><given-names>WC</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Wu</surname><given-names>YY</given-names></name><name><surname>Yang</surname><given-names>CH</given-names></name><name><surname>Ho</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Genetic variants associated with phenytoin-related severe cutaneous adverse reactions</article-title><source>JAMA.</source><year>2014</year><volume>312</volume><fpage>525</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.7859</pub-id><?supplied-pmid 25096692?><pub-id pub-id-type="pmid">25096692</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Depondt</surname><given-names>C</given-names></name><name><surname>Godard</surname><given-names>P</given-names></name><name><surname>Espel</surname><given-names>RS</given-names></name><name><surname>da Cruz</surname><given-names>AL</given-names></name><name><surname>Lienard</surname><given-names>P</given-names></name><name><surname>Pandolfo</surname><given-names>M</given-names></name></person-group><article-title>A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity</article-title><source>Eur J Neurol.</source><year>2011</year><volume>18</volume><fpage>1159</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.2011.03361.x</pub-id><?supplied-pmid 21338443?><pub-id pub-id-type="pmid">21338443</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>JF</given-names></name><name><surname>Qi</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>YQ</given-names></name><name><surname>Wang</surname><given-names>WZ</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name></person-group><article-title>Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration</article-title><source>Zhongua Yi Xue Za Zhi.</source><year>2004</year><volume>84</volume><fpage>1686</fpage><lpage>1689</lpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>CC</given-names></name><name><surname>Lin</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name><name><surname>Chang</surname><given-names>CJ</given-names></name><name><surname>Liou</surname><given-names>HH</given-names></name></person-group><article-title>Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms</article-title><source>Ther Drug Monit.</source><year>2004</year><volume>26</volume><fpage>534</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1097/00007691-200410000-00012</pub-id><?supplied-pmid 15385837?><pub-id pub-id-type="pmid">15385837</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kousar</surname><given-names>S</given-names></name><name><surname>Wafai</surname><given-names>ZA</given-names></name><name><surname>Wani</surname><given-names>MA</given-names></name><name><surname>Jan</surname><given-names>TR</given-names></name><name><surname>Andrabi</surname><given-names>KI</given-names></name></person-group><article-title>Clinical relevance of genetic polymorphism in the CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance</article-title><source>Int J Clin Pharmacol Ther.</source><year>2015</year><volume>53</volume><fpage>504</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.5414/CP202112</pub-id><?supplied-pmid 25943175?><pub-id pub-id-type="pmid">25943175</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kesavan</surname><given-names>R</given-names></name><name><surname>Narayan</surname><given-names>SK</given-names></name><name><surname>Adithan</surname><given-names>C</given-names></name></person-group><article-title>Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients</article-title><source>Eur J Clin Pharmacol.</source><year>2010</year><volume>66</volume><fpage>689</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1007/s00228-010-0817-2</pub-id><?supplied-pmid 20390258?><pub-id pub-id-type="pmid">20390258</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Cao</surname><given-names>BQ</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>SQ</given-names></name><name><surname>Jiang</surname><given-names>DH</given-names></name></person-group><article-title>Association between ABCB1 genetic polymorphism and the effect on epilepsy following phenytoin treatment</article-title><source>Exp Ther Med.</source><year>2016</year><volume>12</volume><fpage>1780</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.3892/etm.2016.3553</pub-id><?supplied-pmid 27602091?><pub-id pub-id-type="pmid">27602091</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Weide</surname><given-names>J</given-names></name><name><surname>Steijns</surname><given-names>LS</given-names></name><name><surname>van Weelden</surname><given-names>MJ</given-names></name><name><surname>de Haan</surname><given-names>K</given-names></name></person-group><article-title>The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement</article-title><source>Pharmacogenetics.</source><year>2001</year><volume>11</volume><fpage>287</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1097/00008571-200106000-00002</pub-id><?supplied-pmid 11434505?><pub-id pub-id-type="pmid">11434505</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponnala</surname><given-names>S</given-names></name><name><surname>Chaudhari</surname><given-names>JR</given-names></name><name><surname>Jaleel</surname><given-names>MA</given-names></name><name><surname>Bhiladvala</surname><given-names>D</given-names></name><name><surname>Kaipa</surname><given-names>PR</given-names></name><name><surname>Das</surname><given-names>UN</given-names></name></person-group><article-title>Role of <italic>MDR1</italic> C3435T and <italic>GABRG2</italic> C588T gene polymorphisms in seizure occurrence and <italic>MDR1</italic> effect on anti-epileptic drug (phenytoin) absorption</article-title><source>Genet Test Mol Biomark.</source><year>2012</year><volume>16</volume><fpage>550</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1089/gtmb.2011.0225</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thaker</surname><given-names>SJ</given-names></name><name><surname>Gandhe</surname><given-names>PP</given-names></name><name><surname>Godbole</surname><given-names>CJ</given-names></name><name><surname>Bendkhale</surname><given-names>SR</given-names></name><name><surname>Mali</surname><given-names>NB</given-names></name><name><surname>Thatte</surname><given-names>UM</given-names></name><etal/></person-group><article-title>A prospective study to assess the association between genotype, phenotype and Prakriti in individuals on phenytoin monotherapy</article-title><source>J Ayurveda Integr Med.</source><year>2017</year><volume>8</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.jaim.2016.12.001</pub-id><?supplied-pmid 28302415?><pub-id pub-id-type="pmid">28302415</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabari</surname><given-names>RG</given-names></name><name><surname>Naseri</surname><given-names>F</given-names></name><name><surname>Marjani</surname><given-names>A</given-names></name></person-group><article-title>Genetic polymorphism of CYPP450 (2C19) enzyme in Iranian Baluch ethnic group</article-title><source>Open Biochem J.</source><year>2015</year><volume>9</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.2174/1874091X01509010037</pub-id><?supplied-pmid 26464589?><pub-id pub-id-type="pmid">26464589</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seven</surname><given-names>M</given-names></name><name><surname>Batar</surname><given-names>B</given-names></name><name><surname>Unal</surname><given-names>S</given-names></name><name><surname>Yesil</surname><given-names>G</given-names></name><name><surname>Yuksel</surname><given-names>A</given-names></name><name><surname>Guven</surname><given-names>M</given-names></name></person-group><article-title>The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children</article-title><source>Mol Diagn Ther.</source><year>2014</year><volume>18</volume><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/s40291-013-0078-8</pub-id><?supplied-pmid 24338437?><pub-id pub-id-type="pmid">24338437</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seven</surname><given-names>M</given-names></name><name><surname>Batar</surname><given-names>B</given-names></name><name><surname>Unal</surname><given-names>S</given-names></name><name><surname>Yesil</surname><given-names>G</given-names></name><name><surname>Yuksel</surname><given-names>A</given-names></name><name><surname>Guven</surname><given-names>M</given-names></name></person-group><article-title>The drug-transporter gene MDR1 C3435T and G2677T/A polymorphisms and the risk of multidrug-resistant epilepsy in Turkish children</article-title><source>Mol Biol Rep.</source><year>2014</year><volume>41</volume><fpage>331</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1007/s11033-013-2866-y</pub-id><?supplied-pmid 24213830?><pub-id pub-id-type="pmid">24213830</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Britzi</surname><given-names>M</given-names></name><name><surname>Bialer</surname><given-names>M</given-names></name><name><surname>Arcavi</surname><given-names>L</given-names></name><name><surname>Shachbari</surname><given-names>A</given-names></name><name><surname>Kapitulnik</surname><given-names>T</given-names></name><name><surname>Soback</surname><given-names>S</given-names></name></person-group><article-title>Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups</article-title><source>Ther Drug Monit.</source><year>2000</year><volume>22</volume><fpage>510</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1097/00007691-200010000-00002</pub-id><?supplied-pmid 11034254?><pub-id pub-id-type="pmid">11034254</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sviri</surname><given-names>S</given-names></name><name><surname>Shpizen</surname><given-names>S</given-names></name><name><surname>Leitersdorf</surname><given-names>E</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Caraco</surname><given-names>Y</given-names></name></person-group><article-title>Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population</article-title><source>Clin Pharmacol Ther.</source><year>1999</year><volume>65</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/S0009-9236(99)70106-2</pub-id><?supplied-pmid 10096259?><pub-id pub-id-type="pmid">10096259</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maleki</surname><given-names>M</given-names></name><name><surname>Sayyah</surname><given-names>M</given-names></name><name><surname>Kamgarpour</surname><given-names>F</given-names></name><name><surname>Karimipoor</surname><given-names>M</given-names></name><name><surname>Arab</surname><given-names>A</given-names></name><name><surname>Rajabi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association between ABCB1-T1236C polymorphism and drug-resistant epilepsy in Iranian female patients</article-title><source>Iran Biomed J.</source><year>2010</year><volume>14</volume><fpage>89</fpage><lpage>96</lpage><?supplied-pmid 21079659?><pub-id pub-id-type="pmid">21079659</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayyah</surname><given-names>M</given-names></name><name><surname>Kamgarpour</surname><given-names>F</given-names></name><name><surname>Maleki</surname><given-names>M</given-names></name><name><surname>Karimipoor</surname><given-names>M</given-names></name><name><surname>Gharagozli</surname><given-names>K</given-names></name><name><surname>Shamshiri</surname><given-names>AR</given-names></name></person-group><article-title>Association analysis of intractable epilepsy with C3435T and G2677T/A ABCB1 gene polymorphisms in Iranian patients</article-title><source>Epileptic Disord.</source><year>2011</year><volume>13</volume><fpage>155</fpage><lpage>165</lpage><?supplied-pmid 21636342?><pub-id pub-id-type="pmid">21636342</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennessy</surname><given-names>S</given-names></name><name><surname>Leonard</surname><given-names>CE</given-names></name><name><surname>Freeman</surname><given-names>CP</given-names></name><name><surname>Metlay</surname><given-names>JP</given-names></name><name><surname>Chu</surname><given-names>X</given-names></name><name><surname>Strom</surname><given-names>BL</given-names></name><name><surname>Bilker</surname><given-names>WB</given-names></name></person-group><article-title>CYP2C9, CYP2C19 and ABCB1 genotype and hospitalization for phenytoin toxicity</article-title><source>Clin Lymphoma</source><year>2010</year><volume>9</volume><fpage>19</fpage><lpage>22</lpage></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>ML</given-names></name><name><surname>Tien</surname><given-names>YE</given-names></name><name><surname>Huang</surname><given-names>YS</given-names></name><name><surname>Huang</surname><given-names>JD</given-names></name></person-group><article-title>Studies on pharmacokinetic mechanism of phenytoin resistance in refractory epilepsy</article-title><source>J Pharm Sci.</source><year>2013</year><volume>102</volume><fpage>3189</fpage><lpage>3195</lpage><pub-id pub-id-type="doi">10.1002/jps.23593</pub-id><?supplied-pmid 23658067?><pub-id pub-id-type="pmid">23658067</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaheen</surname><given-names>U</given-names></name><name><surname>Prasad</surname><given-names>DKV</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Suryaprabha</surname><given-names>T</given-names></name><name><surname>Ahuja</surname><given-names>YR</given-names></name><name><surname>Jyothy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy</article-title><source>Epilepsy Res.</source><year>2014</year><volume>108</volume><fpage>251</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.eplepsyres.2013.11.009</pub-id><?supplied-pmid 24300029?><pub-id pub-id-type="pmid">24300029</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grover</surname><given-names>S</given-names></name><name><surname>Gourie-Devi</surname><given-names>M</given-names></name><name><surname>Baghel</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Bala</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><etal/></person-group><article-title>Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment</article-title><source>Pharmacogenomics.</source><year>2010</year><volume>11</volume><fpage>927</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.2217/pgs.10.62</pub-id><?supplied-pmid 20602612?><pub-id pub-id-type="pmid">20602612</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yampayon</surname><given-names>K</given-names></name><name><surname>Sukasem</surname><given-names>C</given-names></name><name><surname>Limwongse</surname><given-names>C</given-names></name><name><surname>Chinvarun</surname><given-names>Y</given-names></name><name><surname>Tempark</surname><given-names>T</given-names></name><name><surname>Rerkpattanapipat</surname><given-names>T</given-names></name><etal/></person-group><article-title>Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions</article-title><source>Eur J Clin Pharmacol.</source><year>2017</year><volume>73</volume><fpage>855</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1007/s00228-017-2250-2</pub-id><?supplied-pmid 28391407?><pub-id pub-id-type="pmid">28391407</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salehifar</surname><given-names>E</given-names></name><name><surname>Zohrabi</surname><given-names>M</given-names></name><name><surname>Eshghi</surname><given-names>S</given-names></name><name><surname>Saeedi</surname><given-names>M</given-names></name><name><surname>Ebrahimi</surname><given-names>P</given-names></name></person-group><article-title>Different pharmacokinetic parameters of phenytoin in Iranian outpatients: need to optimize the current dosage regimen</article-title><source>IJPR.</source><year>2009</year><volume>8</volume><fpage>37</fpage><lpage>45</lpage></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhazzani</surname><given-names>AA</given-names></name><name><surname>Munisamy</surname><given-names>M</given-names></name><name><surname>Karunakaran</surname><given-names>G</given-names></name></person-group><article-title>Pharmacogenetics of ATP binding cassette transporter&#x02014;MDR1 gene polymorphism (MDR1&#x02014;1236C&#x0003e;T polymorphism) and response to antiepileptic drug phenytoin pharmacokinetics in epilepsy</article-title><source>Neurology.</source><year>2016</year><volume>86</volume><issue>Suppl. 16</issue><fpage>P2.046</fpage></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhazzani</surname><given-names>A</given-names></name><name><surname>Al-Gahtany</surname><given-names>M</given-names></name><name><surname>Munisamy</surname><given-names>M</given-names></name><name><surname>Karunakaran</surname><given-names>G</given-names></name></person-group><article-title>Pharmacogenetics of ATP binding cassette transporter-MDR1 gene polymorphism (C3435T) and response to antiepileptic drug phenytoin pharmacokinetics in epilepsy</article-title><source>J Neurol Sci.</source><year>2015</year><volume>357</volume><fpage>e142</fpage><lpage>e160</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2015.08.486</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aynacioglu</surname><given-names>AS</given-names></name><name><surname>Brockm&#x000f6;ller</surname><given-names>J</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Sachse</surname><given-names>C</given-names></name><name><surname>Guzelbey</surname><given-names>P</given-names></name><name><surname>Ongen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin</article-title><source>Br J Clin Pharmacol.</source><year>1999</year><volume>48</volume><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.1999.00012.x</pub-id><?supplied-pmid 10510154?><pub-id pub-id-type="pmid">10510154</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerb</surname><given-names>R</given-names></name><name><surname>Aynacioglu</surname><given-names>AS</given-names></name><name><surname>Brockm&#x000f6;ller</surname><given-names>J</given-names></name><name><surname>Schlagenhaufer</surname><given-names>R</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Szekeres</surname><given-names>T</given-names></name><etal/></person-group><article-title>The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels</article-title><source>Pharmacogenom J.</source><year>2001</year><volume>1</volume><fpage>204</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1038/sj.tpj.6500025</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozkaynakci</surname><given-names>A</given-names></name><name><surname>Gulcebi</surname><given-names>MI</given-names></name><name><surname>Erge&#x000e7;</surname><given-names>D</given-names></name><name><surname>Ulucan</surname><given-names>K</given-names></name><name><surname>Uzan</surname><given-names>M</given-names></name><name><surname>Ozkara</surname><given-names>C</given-names></name><etal/></person-group><article-title>The effect of polymorphic metabolism enzymes on serum phenytoin level</article-title><source>Neurol Sci.</source><year>2015</year><volume>36</volume><fpage>397</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1007/s10072-014-1961-8</pub-id><?supplied-pmid 25311916?><pub-id pub-id-type="pmid">25311916</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhazzani</surname><given-names>AA</given-names></name><name><surname>Munisamy</surname><given-names>M</given-names></name><name><surname>Karunakaran</surname><given-names>G</given-names></name></person-group><article-title>MDR1 gene polymorphism and phenytoin pharmacokinetics in epilepsy</article-title><source>Bahrain Med Bull.</source><year>2017</year><volume>39</volume><fpage>29</fpage><lpage>32</lpage></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebid</surname><given-names>AH</given-names></name><name><surname>Ahmed</surname><given-names>MM</given-names></name><name><surname>Mohammed</surname><given-names>SA</given-names></name></person-group><article-title>Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study</article-title><source>Ther Drug Monit.</source><year>2007</year><volume>29</volume><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e318067ce90</pub-id><?supplied-pmid 17529887?><pub-id pub-id-type="pmid">17529887</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamdy</surname><given-names>SI</given-names></name><name><surname>Hiratsuka</surname><given-names>M</given-names></name><name><surname>Narahara</surname><given-names>K</given-names></name><name><surname>El-Enany</surname><given-names>M</given-names></name><name><surname>Moursi</surname><given-names>N</given-names></name><name><surname>Ahmed</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, and CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population</article-title><source>Br J Clin Pharmacol.</source><year>2002</year><volume>52</volume><fpage>596</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2002.01604.x</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Din</surname><given-names>MS</given-names></name><name><surname>Amin</surname><given-names>DG</given-names></name><name><surname>Ragab</surname><given-names>SB</given-names></name><name><surname>Ashour</surname><given-names>EE</given-names></name><name><surname>Mohamed</surname><given-names>MH</given-names></name><name><surname>Mohamed</surname><given-names>AM</given-names></name></person-group><article-title>Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen</article-title><source>Int J Lab Hematol.</source><year>2012</year><volume>34</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1111/j.1751-553X.2012.01426.x</pub-id><?supplied-pmid 22533669?><pub-id pub-id-type="pmid">22533669</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzam</surname><given-names>H</given-names></name><name><surname>Elwakeel</surname><given-names>H</given-names></name><name><surname>Awad</surname><given-names>I</given-names></name><name><surname>El-Farahaty</surname><given-names>R</given-names></name><name><surname>El-Gilany</surname><given-names>AH</given-names></name><name><surname>El-Sharawy</surname><given-names>S</given-names></name></person-group><article-title>VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance</article-title><source>Blood Coagul Fibrinolysis.</source><year>2016</year><volume>27</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1097/MBC.0000000000000168</pub-id><?supplied-pmid 24978953?><pub-id pub-id-type="pmid">24978953</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazan</surname><given-names>NS</given-names></name><name><surname>Sabry</surname><given-names>NA</given-names></name><name><surname>Rizk</surname><given-names>A</given-names></name><name><surname>Mokhtar</surname><given-names>S</given-names></name><name><surname>Badary</surname><given-names>OA</given-names></name></person-group><article-title>Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism</article-title><source>Ir J Med Sci.</source><year>2014</year><volume>183</volume><fpage>161</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1007/s11845-013-0978-y</pub-id><?supplied-pmid 23800980?><pub-id pub-id-type="pmid">23800980</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekladious</surname><given-names>SM</given-names></name><name><surname>Issac</surname><given-names>MS</given-names></name><name><surname>Sharaf</surname><given-names>SA</given-names></name><name><surname>Abou-Youssef</surname><given-names>HS</given-names></name></person-group><article-title>Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients</article-title><source>Mol Diagn Ther.</source><year>2013</year><volume>17</volume><fpage>381</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1007/s40291-013-0046-3</pub-id><?supplied-pmid 23839801?><pub-id pub-id-type="pmid">23839801</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahin</surname><given-names>MH</given-names></name><name><surname>Khalifa</surname><given-names>SI</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Hammad</surname><given-names>LN</given-names></name><name><surname>Sallam</surname><given-names>MT</given-names></name><name><surname>Shafey</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients</article-title><source>Pharmacogenet Genom.</source><year>2011</year><volume>21</volume><fpage>130</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1097/FPC.0b013e3283436b86</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zand</surname><given-names>N</given-names></name><name><surname>Tajik</surname><given-names>N</given-names></name><name><surname>Moghaddam</surname><given-names>AS</given-names></name><name><surname>Milanian</surname><given-names>I</given-names></name></person-group><article-title>Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population</article-title><source>Clin Exp Pharmacol Physiol.</source><year>2007</year><volume>34</volume><fpage>102</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2007.04538.x</pub-id><?supplied-pmid 17201743?><pub-id pub-id-type="pmid">17201743</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amini-Shirazi</surname><given-names>N</given-names></name><name><surname>Ghahremani</surname><given-names>MH</given-names></name><name><surname>Ahmadkhaniha</surname><given-names>R</given-names></name><name><surname>Mandegary</surname><given-names>A</given-names></name><name><surname>Dadgar</surname><given-names>A</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients</article-title><source>Toxicol Mech Methods.</source><year>2010</year><volume>20</volume><issue>8</issue><fpage>452</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.3109/15376516.2010.497977</pub-id><?supplied-pmid 20602621?><pub-id pub-id-type="pmid">20602621</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghadam</surname><given-names>P</given-names></name><name><surname>Sharifian</surname><given-names>R</given-names></name><name><surname>Farsangi</surname><given-names>ZJ</given-names></name><name><surname>Kianmehr</surname><given-names>Z</given-names></name><name><surname>Lak</surname><given-names>M</given-names></name></person-group><article-title>CYP2C9 gene analysis of some Iranian hypersensitive patients to warfarin</article-title><source>Pak J Biol Sci.</source><year>2009</year><volume>12</volume><issue>16</issue><fpage>1160</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.3923/pjbs.2009.1160.1163</pub-id><?supplied-pmid 19899329?><pub-id pub-id-type="pmid">19899329</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namazi</surname><given-names>S</given-names></name><name><surname>Azarpira</surname><given-names>N</given-names></name><name><surname>Hendijani</surname><given-names>F</given-names></name><name><surname>Khorshid</surname><given-names>MB</given-names></name><name><surname>Vessal</surname><given-names>G</given-names></name><name><surname>Mehdipour</surname><given-names>AR</given-names></name></person-group><article-title>The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran</article-title><source>Clin Ther.</source><year>2010</year><volume>32</volume><issue>6</issue><fpage>1050</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2010.06.010</pub-id><?supplied-pmid 20637959?><pub-id pub-id-type="pmid">20637959</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousef</surname><given-names>A-M</given-names></name><name><surname>Bulatova</surname><given-names>NR</given-names></name><name><surname>Newman</surname><given-names>W</given-names></name><name><surname>Hakooz</surname><given-names>N</given-names></name><name><surname>Ismail</surname><given-names>S</given-names></name><name><surname>Qusa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population</article-title><source>Mol Biol Rep.</source><year>2012</year><volume>39</volume><issue>10</issue><fpage>9423</fpage><lpage>9433</lpage><pub-id pub-id-type="doi">10.1007/s11033-012-1807-5</pub-id><?supplied-pmid 22722998?><pub-id pub-id-type="pmid">22722998</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alrashid</surname><given-names>MH</given-names></name><name><surname>Al-Serri</surname><given-names>A</given-names></name><name><surname>Alshemmari</surname><given-names>SH</given-names></name><name><surname>Koshi</surname><given-names>P</given-names></name><name><surname>Al-Bustan</surname><given-names>SA</given-names></name></person-group><article-title>Association of genetic polymorphisms in the VKORC1 and CYP2C9 genes with warfarin dosage in a group of Kuwaiti individuals</article-title><source>Mol Diagn Ther.</source><year>2016</year><volume>20</volume><issue>2</issue><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1007/s40291-016-0190-7</pub-id><?supplied-pmid 26940072?><pub-id pub-id-type="pmid">26940072</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djaffar-Jureidini</surname><given-names>I</given-names></name><name><surname>Chamseddine</surname><given-names>N</given-names></name><name><surname>Keleshian</surname><given-names>S</given-names></name><name><surname>Naoufal</surname><given-names>R</given-names></name><name><surname>Zahed</surname><given-names>L</given-names></name><name><surname>Hakime</surname><given-names>N</given-names></name></person-group><article-title>Pharmacogenomics of coumarin dosing: prevalence of CYP2C9 and VKORC1 polymorphisms in the Lebanese population</article-title><source>Genet Test Mol Biomark.</source><year>2011</year><volume>15</volume><issue>11</issue><fpage>827</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1089/gtmb.2010.0248</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esmerian</surname><given-names>MO</given-names></name><name><surname>Mitri</surname><given-names>Z</given-names></name><name><surname>Habbal</surname><given-names>MZ</given-names></name><name><surname>Geryess</surname><given-names>E</given-names></name><name><surname>Zaatari</surname><given-names>G</given-names></name><name><surname>Alam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people</article-title><source>J Clin Pharmacol.</source><year>2011</year><volume>51</volume><issue>10</issue><fpage>1418</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1177/0091270010382910</pub-id><?supplied-pmid 21148049?><pub-id pub-id-type="pmid">21148049</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smires</surname><given-names>FZ</given-names></name><name><surname>Habbal</surname><given-names>R</given-names></name><name><surname>Moreau</surname><given-names>C</given-names></name><name><surname>Assaidi</surname><given-names>A</given-names></name><name><surname>Loriot</surname><given-names>MA</given-names></name><name><surname>Nadifi</surname><given-names>S</given-names></name></person-group><article-title>Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P450 CYP2C9 and 1639G&#x0003e;A of the VKORC1 gene; on acenocoumarol requirement in Moroccan patients</article-title><source>Pathol Biol.</source><year>2013</year><volume>61</volume><issue>3</issue><fpage>88</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.patbio.2012.10.002</pub-id><?supplied-pmid 23201087?><pub-id pub-id-type="pmid">23201087</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathare</surname><given-names>A</given-names></name><name><surname>Khabori</surname><given-names>MA</given-names></name><name><surname>Alkindi</surname><given-names>S</given-names></name><name><surname>Zadjali</surname><given-names>SA</given-names></name><name><surname>Misquith</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients</article-title><source>J Hum Genet.</source><year>2012</year><volume>57</volume><issue>10</issue><fpage>665</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1038/jhg.2012.94</pub-id><?supplied-pmid 22854539?><pub-id pub-id-type="pmid">22854539</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanira</surname><given-names>MO</given-names></name><name><surname>Al-Mukhaini</surname><given-names>MK</given-names></name><name><surname>Al-Hinai</surname><given-names>AT</given-names></name><name><surname>Al Balushi</surname><given-names>KA</given-names></name><name><surname>Ahmed</surname><given-names>IS</given-names></name></person-group><article-title>Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose</article-title><source>Community Genet.</source><year>2006</year><volume>10</volume><issue>1</issue><fpage>32</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1159/000096279</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alzahrani</surname><given-names>AM</given-names></name><name><surname>Ragia</surname><given-names>G</given-names></name><name><surname>Hanieh</surname><given-names>H</given-names></name><name><surname>Manolopoulos</surname><given-names>VG</given-names></name></person-group><article-title>Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia</article-title><source>Biomed Res Int.</source><year>2013</year><volume>2013</volume><fpage>3</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1155/2013/315980</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirghani</surname><given-names>RA</given-names></name><name><surname>Chowdhary</surname><given-names>G</given-names></name><name><surname>Elghazali</surname><given-names>G</given-names></name></person-group><article-title>Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi Population</article-title><source>Basic Clin Pharmacol Toxicol.</source><year>2011</year><volume>109</volume><issue>2</issue><fpage>111</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1111/j.1742-7843.2011.00692.x</pub-id><?supplied-pmid 21371265?><pub-id pub-id-type="pmid">21371265</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrif</surname><given-names>NE</given-names></name><name><surname>Won</surname><given-names>HH</given-names></name><name><surname>Lee</surname><given-names>ST</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>KK</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients</article-title><source>Eur J Clin Pharmacol.</source><year>2011</year><volume>67</volume><issue>11</issue><fpage>1119</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1007/s00228-011-1060-1</pub-id><?supplied-pmid 21590310?><pub-id pub-id-type="pmid">21590310</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelhedi</surname><given-names>R</given-names></name><name><surname>Bouayed</surname><given-names>NA</given-names></name><name><surname>Alfadhli</surname><given-names>S</given-names></name><name><surname>Abid</surname><given-names>L</given-names></name><name><surname>Rebai</surname><given-names>A</given-names></name><name><surname>Kharrat</surname><given-names>N</given-names></name></person-group><article-title>Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations</article-title><source>J Genet.</source><year>2015</year><volume>94</volume><issue>4</issue><fpage>765</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1007/s12041-015-0581-2</pub-id><?supplied-pmid 26690534?><pub-id pub-id-type="pmid">26690534</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>N</given-names></name><name><surname>Erba&#x0011f;ci</surname><given-names>AB</given-names></name><name><surname>Aynacio&#x0011f;lu</surname><given-names>A&#x0015e;</given-names></name></person-group><article-title>Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines</article-title><source>Acta Biochim Pol.</source><year>2001</year><volume>48</volume><issue>3</issue><fpage>775</fpage><lpage>782</lpage><?supplied-pmid 11833786?><pub-id pub-id-type="pmid">11833786</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babaoglu</surname><given-names>MO</given-names></name><name><surname>Yasar</surname><given-names>U</given-names></name><name><surname>Sandberg</surname><given-names>M</given-names></name><name><surname>Eliasson</surname><given-names>E</given-names></name><name><surname>Dahl</surname><given-names>ML</given-names></name><name><surname>Kayaalp</surname><given-names>SO</given-names></name><etal/></person-group><article-title>CYP2C9 genetic variants and losartan oxidation in a Turkish population</article-title><source>Eur J Clin Pharmacol.</source><year>2004</year><volume>60</volume><issue>5</issue><fpage>337</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1007/s00228-004-0785-5</pub-id><?supplied-pmid 15197523?><pub-id pub-id-type="pmid">15197523</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozgon</surname><given-names>GO</given-names></name><name><surname>Langaee</surname><given-names>TY</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Buyru</surname><given-names>N</given-names></name><name><surname>Ulutin</surname><given-names>T</given-names></name><name><surname>Hatemi</surname><given-names>AC</given-names></name><etal/></person-group><article-title>VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients</article-title><source>Eur J Clin Pharmacol.</source><year>2008</year><volume>64</volume><issue>9</issue><fpage>889</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1007/s00228-008-0507-5</pub-id><pub-id pub-id-type="pmid">18542936</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozer</surname><given-names>N</given-names></name><name><surname>Cam</surname><given-names>N</given-names></name><name><surname>Tangurek</surname><given-names>B</given-names></name><name><surname>Ozer</surname><given-names>S</given-names></name><name><surname>Uyarel</surname><given-names>H</given-names></name><name><surname>Oz</surname><given-names>D</given-names></name><etal/></person-group><article-title>The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population</article-title><source>Heart Vessels.</source><year>2010</year><volume>25</volume><issue>2</issue><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1007/s00380-009-1177-7</pub-id><?supplied-pmid 20339978?><pub-id pub-id-type="pmid">20339978</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silan</surname><given-names>C</given-names></name><name><surname>Dogan</surname><given-names>OT</given-names></name><name><surname>Silan</surname><given-names>F</given-names></name><name><surname>Kukulguven</surname><given-names>FM</given-names></name><name><surname>Asgun</surname><given-names>HF</given-names></name><name><surname>Ozdemir</surname><given-names>S</given-names></name><etal/></person-group><article-title>The prevalence of VKORC1 1639 G&#x0003e;A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population</article-title><source>Mol Biol Rep.</source><year>2012</year><volume>39</volume><fpage>11017</fpage><lpage>11022</lpage><pub-id pub-id-type="doi">10.1007/s11033-012-2004-2</pub-id><?supplied-pmid 23065265?><pub-id pub-id-type="pmid">23065265</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellison</surname><given-names>CA</given-names></name><name><surname>Abou El-Ella</surname><given-names>SS</given-names></name><name><surname>Tawfik</surname><given-names>M</given-names></name><name><surname>Lein</surname><given-names>PJ</given-names></name><name><surname>Olson</surname><given-names>JR</given-names></name></person-group><article-title>Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers</article-title><source>J Toxicol Environ Health A.</source><year>2012</year><volume>75</volume><issue>4</issue><fpage>232</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1080/15287394.2012.641201</pub-id><?supplied-pmid 22352331?><pub-id pub-id-type="pmid">22352331</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sameer</surname><given-names>AE</given-names></name><name><surname>Amany</surname><given-names>GM</given-names></name><name><surname>Abdela</surname><given-names>AA</given-names></name><name><surname>Fadel</surname><given-names>SA</given-names></name></person-group><article-title>CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip</article-title><source>Can J Clin Pharmacol.</source><year>2009</year><volume>16</volume><issue>1</issue><fpage>156</fpage><lpage>162</lpage></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payan</surname><given-names>M</given-names></name><name><surname>Rouini</surname><given-names>MR</given-names></name><name><surname>Tajik</surname><given-names>N</given-names></name><name><surname>Ghahremani</surname><given-names>MH</given-names></name><name><surname>Tahvilian</surname><given-names>R</given-names></name></person-group><article-title>Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population</article-title><source>Daru.</source><year>2014</year><volume>22</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1186/s40199-014-0081-6</pub-id><?supplied-pmid 25498969?><pub-id pub-id-type="pmid">25498969</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zendehdel</surname><given-names>N</given-names></name><name><surname>Biramijamal</surname><given-names>F</given-names></name><name><surname>Hossein-Nezhad</surname><given-names>A</given-names></name><name><surname>Zendehdel</surname><given-names>N</given-names></name><name><surname>Sarie</surname><given-names>H</given-names></name><name><surname>Doughaiemoghaddam</surname><given-names>M</given-names></name><etal/></person-group><article-title>Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in iranian patients with erosive reflux esophagitis</article-title><source>Arch Iran Med.</source><year>2010</year><volume>13</volume><issue>5</issue><fpage>406</fpage><lpage>412</lpage><?supplied-pmid 20804307?><pub-id pub-id-type="pmid">20804307</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namazi</surname><given-names>S</given-names></name><name><surname>Kojuri</surname><given-names>J</given-names></name><name><surname>Khalili</surname><given-names>A</given-names></name><name><surname>Azarpira</surname><given-names>N</given-names></name></person-group><article-title>The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients</article-title><source>Biochem Pharmacol.</source><year>2012</year><volume>83</volume><fpage>903</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2012.01.003</pub-id><?supplied-pmid 22265638?><pub-id pub-id-type="pmid">22265638</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhlaghi</surname><given-names>A</given-names></name><name><surname>Shirani</surname><given-names>S</given-names></name><name><surname>Ziaie</surname><given-names>N</given-names></name><name><surname>Pirhaji</surname><given-names>O</given-names></name><name><surname>Yaran</surname><given-names>M</given-names></name><name><surname>Shahverdi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease</article-title><source>ARYA Atheroscler.</source><year>2011</year><volume>7</volume><issue>3</issue><fpage>106</fpage><lpage>110</lpage><?supplied-pmid 22577456?><pub-id pub-id-type="pmid">22577456</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nozari</surname><given-names>Y</given-names></name><name><surname>Vosooghi</surname><given-names>S</given-names></name><name><surname>Boroumand</surname><given-names>M</given-names></name><name><surname>Poorhosseini</surname><given-names>H</given-names></name><name><surname>Nematipour</surname><given-names>E</given-names></name><name><surname>Salarifar</surname><given-names>M</given-names></name><etal/></person-group><article-title>The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: a case-match study</article-title><source>Anatol J Cardiol.</source><year>2015</year><volume>15</volume><fpage>348</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.5152/akd.2014.5418</pub-id><?supplied-pmid 25993709?><pub-id pub-id-type="pmid">25993709</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sviri</surname><given-names>S</given-names></name><name><surname>Shpizen</surname><given-names>S</given-names></name><name><surname>Leitersdorf</surname><given-names>E</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Caraco</surname><given-names>Y</given-names></name></person-group><article-title>Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population</article-title><source>Clin Pharmacol Ther.</source><year>1999</year><volume>65</volume><issue>3</issue><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/S0009-9236(99)70106-2</pub-id><?supplied-pmid 10096259?><pub-id pub-id-type="pmid">10096259</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>HR</given-names></name><name><surname>Aloumanis</surname><given-names>V</given-names></name><name><surname>Lin</surname><given-names>KM</given-names></name><name><surname>Gurwitz</surname><given-names>D</given-names></name><name><surname>Wan</surname><given-names>YJ</given-names></name></person-group><article-title>Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups</article-title><source>Am J Pharmacogenom.</source><year>2004</year><volume>4</volume><issue>6</issue><fpage>395</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.2165/00129785-200404060-00006</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zalloum</surname><given-names>I</given-names></name><name><surname>Hakooz</surname><given-names>N</given-names></name><name><surname>Arafat</surname><given-names>T</given-names></name></person-group><article-title>Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole</article-title><source>Mol Biol Rep.</source><year>2012</year><volume>39</volume><issue>4</issue><fpage>4195</fpage><lpage>4200</lpage><pub-id pub-id-type="doi">10.1007/s11033-011-1204-5</pub-id><?supplied-pmid 21769476?><pub-id pub-id-type="pmid">21769476</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jureidini</surname><given-names>ID</given-names></name><name><surname>Chamseddine</surname><given-names>N</given-names></name><name><surname>Keleshian</surname><given-names>S</given-names></name><name><surname>Naoufal</surname><given-names>R</given-names></name><name><surname>Zahed</surname><given-names>L</given-names></name><name><surname>Hakime</surname><given-names>N</given-names></name></person-group><article-title>Prevalence of CYP2C19 polymorphisms in the Lebanese population</article-title><source>Mol Biol Rep.</source><year>2011</year><volume>38</volume><issue>8</issue><fpage>5449</fpage><lpage>5452</lpage><pub-id pub-id-type="doi">10.1007/s11033-011-0700-y</pub-id><pub-id pub-id-type="pmid">21380557</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeed</surname><given-names>LH</given-names></name><name><surname>Mayet</surname><given-names>AY</given-names></name></person-group><article-title>Genotype-phenotype analysis of CYP2C19 in healthy Saudi individuals and its potential clinical implication in drug therapy</article-title><source>Int J Med Sci.</source><year>2013</year><volume>10</volume><issue>11</issue><fpage>1497</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.7150/ijms.6795</pub-id><?supplied-pmid 24046523?><pub-id pub-id-type="pmid">24046523</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>JA</given-names></name><name><surname>Ishizaki</surname><given-names>T</given-names></name><name><surname>Chiba</surname><given-names>K</given-names></name><name><surname>de Morais</surname><given-names>SM</given-names></name><name><surname>Bell</surname><given-names>D</given-names></name><name><surname>Krahn</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Frequencies of defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations</article-title><source>Pharmacogenetics.</source><year>1997</year><volume>7</volume><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1097/00008571-199702000-00008</pub-id><?supplied-pmid 9110363?><pub-id pub-id-type="pmid">9110363</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalaf</surname><given-names>H</given-names></name><name><surname>Al Meman</surname><given-names>AR</given-names></name><name><surname>Rasool</surname><given-names>S</given-names></name></person-group><article-title>Impact of cytochrome P450 2C19*2 and *3 on clopidogrel loading dose in Saudi patients with acute coronary syndrome</article-title><source>Drug Metab Lett.</source><year>2016</year><volume>10</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.2174/1872312810666151117122841</pub-id><?supplied-pmid 26573281?><pub-id pub-id-type="pmid">26573281</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aynacioglu</surname><given-names>AS</given-names></name><name><surname>Sachse</surname><given-names>C</given-names></name><name><surname>Bozkurt</surname><given-names>A</given-names></name><name><surname>Kortunay</surname><given-names>S</given-names></name><name><surname>Nacak</surname><given-names>M</given-names></name><name><surname>Schroder</surname><given-names>T</given-names></name><etal/></person-group><article-title>Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population</article-title><source>Clin Pharmacol Ther.</source><year>1999</year><volume>66</volume><issue>2</issue><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1053/cp.1999.v66.100072001</pub-id><?supplied-pmid 10460072?><pub-id pub-id-type="pmid">10460072</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gumus</surname><given-names>E</given-names></name><name><surname>Karaca</surname><given-names>O</given-names></name><name><surname>Babaoglu</surname><given-names>MO</given-names></name><name><surname>Baysoy</surname><given-names>G</given-names></name><name><surname>Balamtekin</surname><given-names>N</given-names></name><name><surname>Demir</surname><given-names>H</given-names></name><etal/></person-group><article-title>Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood</article-title><source>Eur J Clin Pharmacol.</source><year>2012</year><volume>68</volume><issue>5</issue><fpage>629</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1007/s00228-011-1151-z</pub-id><?supplied-pmid 22076562?><pub-id pub-id-type="pmid">22076562</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>HM</given-names></name><name><surname>Silan</surname><given-names>F</given-names></name><name><surname>Silan</surname><given-names>C</given-names></name><name><surname>Degirmenci</surname><given-names>Y</given-names></name><name><surname>Ozisik Kamaran</surname><given-names>HI</given-names></name></person-group><article-title>Effects of CYP2C19 and P2Y12 gene polymorphisms on clinical results of patients using clopidogrel after acute ischemic cerebrovascular disease</article-title><source>Balkan J Med Genet.</source><year>2014</year><volume>17</volume><issue>2</issue><fpage>37</fpage><lpage>41</lpage><?supplied-pmid 25937796?><pub-id pub-id-type="pmid">25937796</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>BM</given-names></name><name><surname>Shahin</surname><given-names>MH</given-names></name><name><surname>Solayman</surname><given-names>MHF</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Hammad</surname><given-names>LN</given-names></name><name><surname>Al-Mesallamy</surname><given-names>HO</given-names></name><etal/></person-group><article-title>Genetic and nongenetic factors affecting clopidogrel response in the Egyptian population</article-title><source>Clin Transl Sci.</source><year>2016</year><volume>9</volume><issue>1</issue><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1111/cts.12383</pub-id><?supplied-pmid 26757134?><pub-id pub-id-type="pmid">26757134</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Issac</surname><given-names>MS</given-names></name><name><surname>El-Nahid</surname><given-names>MS</given-names></name><name><surname>Wissa</surname><given-names>MY</given-names></name></person-group><article-title>Is there a role for MDR1, EPHX1 and Protein Z gene variants in modulation of warfarin dosage? A study on a cohort of the Egyptian population</article-title><source>Mol Diagn Ther.</source><year>2014</year><volume>18</volume><issue>1</issue><fpage>73</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s40291-013-0055-2</pub-id><?supplied-pmid 24092646?><pub-id pub-id-type="pmid">24092646</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shabana</surname><given-names>MF</given-names></name><name><surname>Mishriki</surname><given-names>AA</given-names></name><name><surname>Issac</surname><given-names>MS</given-names></name><name><surname>Bakhoum</surname><given-names>SW</given-names></name></person-group><article-title>Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia</article-title><source>Mol Diagn Ther.</source><year>2013</year><volume>17</volume><issue>5</issue><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1007/s40291-013-0038-3</pub-id><?supplied-pmid 23677857?><pub-id pub-id-type="pmid">23677857</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>MA</given-names></name><name><surname>Elsalakawy</surname><given-names>WA</given-names></name></person-group><article-title>ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate</article-title><source>Med Oncol.</source><year>2014</year><volume>31</volume><issue>11</issue><fpage>279</fpage><pub-id pub-id-type="doi">10.1007/s12032-014-0279-y</pub-id><?supplied-pmid 25301112?><pub-id pub-id-type="pmid">25301112</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Beblawy</surname><given-names>NM</given-names></name><name><surname>Elbarbary</surname><given-names>NS</given-names></name><name><surname>Kamal</surname><given-names>TM</given-names></name><name><surname>Mahmoud</surname><given-names>PM</given-names></name></person-group><article-title>A study of human killer cell immunoglobulin-like receptor and multidrug resistance gene polymorphisms in children with immune thrombocytopenia</article-title><source>Clin Appl Thromb Hemost.</source><year>2016</year><volume>22</volume><issue>5</issue><fpage>429</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1177/1076029615576738</pub-id><?supplied-pmid 25792670?><pub-id pub-id-type="pmid">25792670</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saidijam</surname><given-names>M</given-names></name><name><surname>Mahjub</surname><given-names>H</given-names></name><name><surname>Shabab</surname><given-names>N</given-names></name><name><surname>Yadegarazari</surname><given-names>R</given-names></name></person-group><article-title>Simultaneous analysis of multidrug resistance 1 (MDR1) C3435T, G2677T/A, and C1236T genotypes in Hamadan city population, West of Iran</article-title><source>Iran Biomed J.</source><year>2015</year><volume>19</volume><issue>1</issue><fpage>57</fpage><lpage>62</lpage><?supplied-pmid 25605491?><pub-id pub-id-type="pmid">25605491</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayyah</surname><given-names>M</given-names></name><name><surname>Kamgarpour</surname><given-names>F</given-names></name><name><surname>Maleki</surname><given-names>M</given-names></name><name><surname>Karimipoor</surname><given-names>M</given-names></name><name><surname>Gharagozli</surname><given-names>K</given-names></name><name><surname>Shamshiri</surname><given-names>AR</given-names></name></person-group><article-title>Association analysis of intractable epilepsy with C3435T and G2677T/A ABCB1 gene polymorphisms in Iranian patients</article-title><source>Epileptic Disord.</source><year>2011</year><volume>13</volume><issue>2</issue><fpage>155</fpage><lpage>165</lpage><?supplied-pmid 21636342?><pub-id pub-id-type="pmid">21636342</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonyadi</surname><given-names>M</given-names></name><name><surname>Gholizadeh</surname><given-names>M</given-names></name><name><surname>Soltan-Ali</surname><given-names>M</given-names></name></person-group><article-title>MDR1 C3435T polymorphism associated with the development of clinical features in Beh&#x000e7;et&#x02019;s disease in Iranian Azeri Turkish patients</article-title><source>Int J Dermatol.</source><year>2014</year><volume>53</volume><fpage>1235</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1111/ijd.12540</pub-id><?supplied-pmid 24898446?><pub-id pub-id-type="pmid">24898446</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghafouri</surname><given-names>H</given-names></name><name><surname>Ghaderi</surname><given-names>B</given-names></name><name><surname>Amini</surname><given-names>S</given-names></name><name><surname>Nikkhoo</surname><given-names>B</given-names></name><name><surname>Abdi</surname><given-names>M</given-names></name><name><surname>Hoseini</surname><given-names>A</given-names></name></person-group><article-title>Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer</article-title><source>Tumor Biol</source><year>2016</year><volume>37</volume><issue>6</issue><fpage>7901</fpage><lpage>7906</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-4679-1</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taheri</surname><given-names>M</given-names></name><name><surname>Mahjoubi</surname><given-names>F</given-names></name><name><surname>Omranipour</surname><given-names>R</given-names></name></person-group><article-title>Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients</article-title><source>Genet Mol Res.</source><year>2010</year><volume>9</volume><issue>1</issue><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.4238/vol9-1gmr669</pub-id><?supplied-pmid 20082268?><pub-id pub-id-type="pmid">20082268</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatari</surname><given-names>F</given-names></name><name><surname>Salek</surname><given-names>R</given-names></name><name><surname>Mosaffa</surname><given-names>F</given-names></name><name><surname>Khedri</surname><given-names>A</given-names></name><name><surname>Behravan</surname><given-names>J</given-names></name></person-group><article-title>Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population</article-title><source>DNA Cell Biol.</source><year>2009</year><volume>28</volume><issue>5</issue><fpage>259</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1089/dna.2008.0826</pub-id><?supplied-pmid 19388849?><pub-id pub-id-type="pmid">19388849</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khabour</surname><given-names>OF</given-names></name><name><surname>Alzoubi</surname><given-names>KH</given-names></name><name><surname>Al-Azzam</surname><given-names>SI</given-names></name><name><surname>Mhaidat</surname><given-names>NM</given-names></name></person-group><article-title>Frequency of MDR1 single nucleotide polymorphisms in a Jordanian population, including a novel variant</article-title><source>Genet Mol Res.</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>801</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.4238/2013.March.13.9</pub-id><?supplied-pmid 23546964?><pub-id pub-id-type="pmid">23546964</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alzoubi</surname><given-names>KH</given-names></name><name><surname>Khabour</surname><given-names>OF</given-names></name><name><surname>Al-Azzam</surname><given-names>SI</given-names></name><name><surname>Mayyas</surname><given-names>F</given-names></name></person-group><article-title>The role of multidrug resistance-1 (MDR1) variants in response to fexofenadine among Jordanians</article-title><source>Int J Clin Pharmacol Ther.</source><year>2013</year><volume>51</volume><issue>11</issue><fpage>880</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.5414/CP201968</pub-id><?supplied-pmid 24040855?><pub-id pub-id-type="pmid">24040855</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samara</surname><given-names>SA</given-names></name><name><surname>Irshaid</surname><given-names>YM</given-names></name><name><surname>Mustafa</surname><given-names>KN</given-names></name></person-group><article-title>Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients</article-title><source>Int J Clin Pharmacol Ther.</source><year>2014</year><volume>52</volume><issue>9</issue><fpage>746</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.5414/CP202098</pub-id><?supplied-pmid 25074866?><pub-id pub-id-type="pmid">25074866</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abuhaliema</surname><given-names>AM</given-names></name><name><surname>Yousef</surname><given-names>AM</given-names></name><name><surname>El-Madany</surname><given-names>NN</given-names></name><name><surname>Bulatova</surname><given-names>NR</given-names></name><name><surname>Awwad</surname><given-names>NM</given-names></name><name><surname>Yousef</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Influence of genotype and haplotype of MDR1 (C3435T, G2677A/T, C1236T) on the incidence of breast cancer: a case-control study in Jordan</article-title><source>Asian Pacific J Cancer Prev.</source><year>2016</year><volume>17</volume><issue>1</issue><fpage>261</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2016.17.1.261</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zgheib</surname><given-names>NK</given-names></name><name><surname>Akra-Ismail</surname><given-names>M</given-names></name><name><surname>Aridi</surname><given-names>C</given-names></name><name><surname>Mahfouz</surname><given-names>R</given-names></name><name><surname>Abboud</surname><given-names>MR</given-names></name><name><surname>Solh</surname><given-names>H</given-names></name><etal/></person-group><article-title>Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia</article-title><source>Pharmacogenet Genomics.</source><year>2014</year><volume>24</volume><issue>8</issue><fpage>387</fpage><lpage>396</lpage><?supplied-pmid 25007187?><pub-id pub-id-type="pmid">25007187</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassogue</surname><given-names>Y</given-names></name><name><surname>Dehbi</surname><given-names>H</given-names></name><name><surname>Nassereddine</surname><given-names>S</given-names></name><name><surname>Quachouh</surname><given-names>M</given-names></name><name><surname>Nadifi</surname><given-names>S</given-names></name></person-group><article-title>Genotype variability and haplotype frequency of MDR1 (ABCB1) gene polymorphism in Morocco</article-title><source>DNA Cell Biol.</source><year>2013</year><volume>32</volume><issue>10</issue><fpage>582</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1089/dna.2013.2108</pub-id><?supplied-pmid 23930592?><pub-id pub-id-type="pmid">23930592</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Mohizea</surname><given-names>AM</given-names></name><name><surname>Alkharfy</surname><given-names>KM</given-names></name><name><surname>Bagulb</surname><given-names>KM</given-names></name><name><surname>Alghamdi</surname><given-names>AM</given-names></name><name><surname>Al-Jenoobi</surname><given-names>FI</given-names></name><name><surname>Al-Muhsen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genetic variability and haplotype profile of MDR1 in Saudi Arabian males</article-title><source>Mol Biol Rep.</source><year>2012</year><volume>39</volume><fpage>10294</fpage><lpage>10301</lpage><pub-id pub-id-type="doi">10.1007/s11033-012-1906-3</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsaif</surname><given-names>AA</given-names></name><name><surname>Hasan</surname><given-names>TN</given-names></name><name><surname>Shafi</surname><given-names>G</given-names></name><name><surname>Syed</surname><given-names>NA</given-names></name><name><surname>Alsaif</surname><given-names>MA</given-names></name><name><surname>Al-Assaf</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association of multiple drug resistance-1 gene polymorphism with multiple drug resistance in breast cancer patients from an ethnic Saudi Arabian population</article-title><source>Cancer Epidemiol.</source><year>2013</year><volume>37</volume><issue>5</issue><fpage>762</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1016/j.canep.2013.04.011</pub-id><?supplied-pmid 23725642?><pub-id pub-id-type="pmid">23725642</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000fc;m&#x000fc;&#x0015f;-Akay</surname><given-names>G</given-names></name><name><surname>R&#x000fc;stemo&#x0011f;lu</surname><given-names>A</given-names></name><name><surname>Karada&#x0011f;</surname><given-names>A</given-names></name><name><surname>Sunguro&#x0011f;lu</surname><given-names>A</given-names></name></person-group><article-title>Haplotype-based analysis of MDR1/ABCB1 gene polymorphisms in a Turkish population</article-title><source>DNA Cell Biol.</source><year>2010</year><volume>29</volume><issue>2</issue><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1089/dna.2009.0953</pub-id><?supplied-pmid 20025534?><pub-id pub-id-type="pmid">20025534</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozgon</surname><given-names>GO</given-names></name><name><surname>Bebek</surname><given-names>N</given-names></name><name><surname>Gul</surname><given-names>G</given-names></name><name><surname>Cine</surname><given-names>N</given-names></name></person-group><article-title>Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey</article-title><source>Eur Neurol.</source><year>2008</year><volume>59</volume><issue>1&#x02013;2</issue><fpage>67</fpage><lpage>70</lpage><?supplied-pmid 17917461?><pub-id pub-id-type="pmid">17917461</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kesimci</surname><given-names>E</given-names></name><name><surname>Engin</surname><given-names>AB</given-names></name><name><surname>Kanbak</surname><given-names>O</given-names></name><name><surname>Karahalil</surname><given-names>B</given-names></name></person-group><article-title>Association between ABCB1 gene polymorphisms and fentanyl&#x02019;s adverse effects in Turkish patients undergoing spinal anesthesia</article-title><source>Gene.</source><year>2012</year><volume>493</volume><issue>2</issue><fpage>273</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2011.11.040</pub-id><?supplied-pmid 22197686?><pub-id pub-id-type="pmid">22197686</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayaz</surname><given-names>G</given-names></name><name><surname>Batar</surname><given-names>B</given-names></name><name><surname>Kanigur</surname><given-names>G</given-names></name><name><surname>Guven</surname><given-names>M</given-names></name><name><surname>Onaran</surname><given-names>I</given-names></name><name><surname>Karadag</surname><given-names>B</given-names></name><etal/></person-group><article-title>The association of MDR1 C3435T and G2677T/A polymorphisms with plasma platelet-activating factor levels and coronary artery disease risk in Turkish population</article-title><source>Gene.</source><year>2013</year><volume>527</volume><issue>1</issue><fpage>301</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2013.06.046</pub-id><?supplied-pmid 23816407?><pub-id pub-id-type="pmid">23816407</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydos</surname><given-names>SE</given-names></name><name><surname>Karada&#x0011f;</surname><given-names>A</given-names></name><name><surname>&#x000d6;zkan</surname><given-names>T</given-names></name><name><surname>Alt&#x00131;nok</surname><given-names>B</given-names></name><name><surname>Bunsuz</surname><given-names>M</given-names></name><name><surname>Heidargholizadeh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association of MDR1 C3435T and C1236T single nucleotide polymorphisms with male factor infertility</article-title><source>Genet Mol Res.</source><year>2015</year><volume>14</volume><issue>2</issue><fpage>6330</fpage><lpage>6339</lpage><pub-id pub-id-type="doi">10.4238/2015.June.11.8</pub-id><?supplied-pmid 26125837?><pub-id pub-id-type="pmid">26125837</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rustemoglu</surname><given-names>A</given-names></name><name><surname>Gumus-Akay</surname><given-names>G</given-names></name><name><surname>Yigit</surname><given-names>S</given-names></name><name><surname>Tasliyurt</surname><given-names>T</given-names></name></person-group><article-title>Analysis of common MDR1 (ABCB1) gene C1236T and C3435T polymorphisms in Turkish patients with familial mediterranean fever</article-title><source>Genet Mol Res.</source><year>2011</year><volume>10</volume><issue>4</issue><fpage>3411</fpage><lpage>3420</lpage><pub-id pub-id-type="doi">10.4238/2011.December.14.7</pub-id><?supplied-pmid 22194207?><pub-id pub-id-type="pmid">22194207</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rustemoglu</surname><given-names>A</given-names></name><name><surname>Gumus-Akay</surname><given-names>G</given-names></name><name><surname>Karakus</surname><given-names>N</given-names></name><name><surname>Yigit</surname><given-names>S</given-names></name><name><surname>Sahin</surname><given-names>S</given-names></name><name><surname>Tasliyurt</surname><given-names>T</given-names></name></person-group><article-title>Association analysis of three ABCB1 (MDR1) gene variants (C1236T, G2677A/T and C3435T) and their genotype/haplotype combinations with the familial Mediterranean fever</article-title><source>Xenobiotica.</source><year>2014</year><volume>44</volume><issue>10</issue><fpage>933</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.3109/00498254.2014.915071</pub-id><?supplied-pmid 24773260?><pub-id pub-id-type="pmid">24773260</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogruer</surname><given-names>D</given-names></name><name><surname>Tug</surname><given-names>E</given-names></name><name><surname>Bes</surname><given-names>C</given-names></name><name><surname>Soy</surname><given-names>M</given-names></name></person-group><article-title>Lack of an effect of CYP3A4 and MDR1 gene polymorphisms on colchicine pharmacogenetics in the treatment of familial Mediterranean fever</article-title><source>Genet Mol Res.</source><year>2013</year><volume>12</volume><issue>3</issue><fpage>3521</fpage><lpage>3528</lpage><pub-id pub-id-type="doi">10.4238/2013.January.24.2</pub-id><?supplied-pmid 23408444?><pub-id pub-id-type="pmid">23408444</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbas</surname><given-names>SH</given-names></name><name><surname>Bilgen</surname><given-names>T</given-names></name><name><surname>Keser</surname><given-names>I</given-names></name><name><surname>Tuncer</surname><given-names>M</given-names></name><name><surname>Yucetin</surname><given-names>L</given-names></name><name><surname>Tosun</surname><given-names>O</given-names></name><etal/></person-group><article-title>The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients</article-title><source>Transplant Proc.</source><year>2006</year><volume>38</volume><issue>5</issue><fpage>1290</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2006.02.079</pub-id><?supplied-pmid 16797284?><pub-id pub-id-type="pmid">16797284</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazancioglu</surname><given-names>HO</given-names></name><name><surname>Ak</surname><given-names>G</given-names></name><name><surname>Turkmen</surname><given-names>A</given-names></name><name><surname>Ozbek</surname><given-names>U</given-names></name><name><surname>Tuncer</surname><given-names>FN</given-names></name><name><surname>Karabulut</surname><given-names>A</given-names></name></person-group><article-title>The role of MDR1 C3435T gene polymorphism on gingival hyperplasia in Turkish renal transplant patients treated with cyclosporine in the absence of calcium channel blockers</article-title><source>Transplant Proc.</source><year>2013</year><volume>45</volume><issue>6</issue><fpage>2233</fpage><lpage>2237</lpage><pub-id pub-id-type="doi">10.1016/j.transproceed.2012.12.007</pub-id><?supplied-pmid 23756537?><pub-id pub-id-type="pmid">23756537</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ya&#x0011f;cio&#x0011f;lu</surname><given-names>AE</given-names></name><name><surname>Yoca</surname><given-names>G</given-names></name><name><surname>Ayhan</surname><given-names>Y</given-names></name><name><surname>Karaca</surname><given-names>R&#x000d6;</given-names></name><name><surname>&#x000c7;evik</surname><given-names>L</given-names></name><name><surname>M&#x000fc;derriso&#x0011f;lu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Relation of the allelic variants of multidrug resistance gene to agranulocytosis associated with clozapine</article-title><source>J Clin Psychopharmacol.</source><year>2016</year><volume>36</volume><issue>3</issue><fpage>257</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1097/JCP.0000000000000495</pub-id><pub-id pub-id-type="pmid">27043126</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogu</surname><given-names>GG</given-names></name><name><surname>Kargi</surname><given-names>A</given-names></name><name><surname>Turgut</surname><given-names>S</given-names></name><name><surname>Ayada</surname><given-names>C</given-names></name><name><surname>Taskoylu</surname><given-names>BY</given-names></name><name><surname>Demiray</surname><given-names>G</given-names></name><etal/></person-group><article-title>MDR1 single nucleotide polymorphism C3435T in Turkish patients with non-small-cell lung cancer</article-title><source>Gene.</source><year>2012</year><volume>506</volume><issue>2</issue><fpage>404</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2012.06.057</pub-id><?supplied-pmid 22766400?><pub-id pub-id-type="pmid">22766400</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zhan</surname><given-names>G</given-names></name><name><surname>Kara</surname><given-names>M</given-names></name><name><surname>Sari</surname><given-names>FM</given-names></name><name><surname>Yanar</surname><given-names>HT</given-names></name><name><surname>Ercan</surname><given-names>G</given-names></name><name><surname>Alpertunga</surname><given-names>B</given-names></name></person-group><article-title>Associations between the functional polymorphisms in the ABCB1 transporter gene and colorectal cancer risk: a case-control study in Turkish population</article-title><source>Toxicol Mech Methods.</source><year>2013</year><volume>23</volume><issue>4</issue><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.3109/15376516.2012.743639</pub-id><?supplied-pmid 23193993?><pub-id pub-id-type="pmid">23193993</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saruwatari</surname><given-names>J</given-names></name><name><surname>Ishitsu</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name></person-group><article-title>Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy</article-title><source>Pharmaceuticals.</source><year>2010</year><volume>3</volume><fpage>2709</fpage><lpage>2732</lpage><pub-id pub-id-type="doi">10.3390/ph3082709</pub-id><?supplied-pmid 27713373?><pub-id pub-id-type="pmid">27713373</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><mixed-citation publication-type="other">PharmGKB. CYP2C9. 2017. <ext-link ext-link-type="uri" xlink:href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</ext-link>. Accessed 25 Feb 2017.</mixed-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Lu</surname><given-names>AY</given-names></name></person-group><article-title>Pharmacogenetics, pharmacogenomics, and individualized medicine</article-title><source>Pharmacol Rev.</source><year>2011</year><volume>63</volume><fpage>437</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1124/pr.110.003533</pub-id><?supplied-pmid 21436344?><pub-id pub-id-type="pmid">21436344</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanger</surname><given-names>UM</given-names></name><name><surname>Turpeinen</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>K</given-names></name><name><surname>Schwab</surname><given-names>M</given-names></name></person-group><article-title>Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation</article-title><source>Anal Bioanal Chem.</source><year>2008</year><volume>392</volume><fpage>1093</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1007/s00216-008-2291-6</pub-id><?supplied-pmid 18695978?><pub-id pub-id-type="pmid">18695978</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rettie</surname><given-names>AE</given-names></name><name><surname>Haining</surname><given-names>RL</given-names></name><name><surname>Bajpai</surname><given-names>M</given-names></name><name><surname>Levy</surname><given-names>RH</given-names></name></person-group><article-title>A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin</article-title><source>Epilepsy Res.</source><year>1999</year><volume>35</volume><fpage>253</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/S0920-1211(99)00017-0</pub-id><?supplied-pmid 10413320?><pub-id pub-id-type="pmid">10413320</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajpai</surname><given-names>M</given-names></name><name><surname>Roskos</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>D</given-names></name><name><surname>Levy</surname><given-names>R</given-names></name></person-group><article-title>Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite</article-title><source>Drug Metab Dispos.</source><year>1996</year><volume>24</volume><issue>12</issue><fpage>1401</fpage><lpage>1403</lpage><?supplied-pmid 8971149?><pub-id pub-id-type="pmid">8971149</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luna-Tort&#x000f3;s</surname><given-names>C</given-names></name><name><surname>Fedrowitz</surname><given-names>M</given-names></name><name><surname>L&#x000f6;scher</surname><given-names>W</given-names></name></person-group><article-title>Several major antiepileptic drugs are substrates for human P-glycoprotein</article-title><source>Neuropharmacology.</source><year>2008</year><volume>55</volume><fpage>1364</fpage><lpage>1375</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.08.032</pub-id><?supplied-pmid 18824002?><pub-id pub-id-type="pmid">18824002</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Kwan</surname><given-names>P</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Baum</surname><given-names>L</given-names></name></person-group><article-title>In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein</article-title><source>Life Sci.</source><year>2010</year><volume>86</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2010.04.008</pub-id><?supplied-pmid 20417647?><pub-id pub-id-type="pmid">20417647</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmeyer</surname><given-names>S</given-names></name><name><surname>Burk</surname><given-names>O</given-names></name><name><surname>von Richter</surname><given-names>O</given-names></name><name><surname>Arnold</surname><given-names>HP</given-names></name><name><surname>Brockm&#x000f6;ller</surname><given-names>J</given-names></name><name><surname>Johne</surname><given-names>A</given-names></name><etal/></person-group><article-title>Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>3473</fpage><lpage>3478</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.7.3473</pub-id><?supplied-pmid 10716719?><pub-id pub-id-type="pmid">10716719</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimchi-Sarfaty</surname><given-names>C</given-names></name><name><surname>Oh</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>IW</given-names></name><name><surname>Sauna</surname><given-names>ZE</given-names></name><name><surname>Calcagno</surname><given-names>AM</given-names></name><name><surname>Ambudkar</surname><given-names>SV</given-names></name><etal/></person-group><article-title>A &#x0201c;silent&#x0201d; polymorphism in the <italic>MDR1</italic> gene changes substrate specificity</article-title><source>Science.</source><year>2007</year><volume>315</volume><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1126/science.1135308</pub-id><?supplied-pmid 17185560?><pub-id pub-id-type="pmid">17185560</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name></person-group><article-title>The roles of variants in human multidrug resistance (MDR1) gene and their haplotypes on antiepileptic drugs response: a meta-analysis of 57 studies</article-title><source>PLoS One.</source><year>2015</year><volume>10</volume><fpage>1</fpage><lpage>16</lpage></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakkar</surname><given-names>AN</given-names></name><name><surname>Bendkhale</surname><given-names>SR</given-names></name><name><surname>Taur</surname><given-names>SR</given-names></name><name><surname>Gogtay</surname><given-names>NJ</given-names></name><name><surname>Thatte</surname><given-names>UM</given-names></name></person-group><article-title>Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients</article-title><source>Neurol India.</source><year>2012</year><volume>60</volume><fpage>577</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.4103/0028-3886.105189</pub-id><?supplied-pmid 23287317?><pub-id pub-id-type="pmid">23287317</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suvichapanic</surname><given-names>S</given-names></name><name><surname>Jittikoon</surname><given-names>J</given-names></name><name><surname>Wichukchinda</surname><given-names>N</given-names></name><name><surname>Kamchaisatian</surname><given-names>W</given-names></name><name><surname>Visudtbhan</surname><given-names>A</given-names></name><name><surname>Benjapopitak</surname><given-names>S</given-names></name><etal/></person-group><article-title>Association analysis of <italic>CYP2C9*3</italic> and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children</article-title><source>J Hum Genet.</source><year>2015</year><volume>60</volume><fpage>413</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1038/jhg.2015.47</pub-id><pub-id pub-id-type="pmid">25994870</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loscher</surname><given-names>W</given-names></name><name><surname>Potschka</surname><given-names>H</given-names></name></person-group><article-title>Role of multidrug transporters in pharmacoresistance to antiepileptic drugs</article-title><source>J Pharmacol Exp Ther.</source><year>2002</year><volume>301</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1124/jpet.301.1.7</pub-id><?supplied-pmid 11907151?><pub-id pub-id-type="pmid">11907151</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sisodiya</surname><given-names>SM</given-names></name><name><surname>Lin</surname><given-names>WR</given-names></name><name><surname>Harding</surname><given-names>BN</given-names></name><name><surname>Squier</surname><given-names>MV</given-names></name><name><surname>Thom</surname><given-names>M</given-names></name></person-group><article-title>Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy</article-title><source>Brain.</source><year>2002</year><volume>125</volume><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1093/brain/awf002</pub-id><?supplied-pmid 11834590?><pub-id pub-id-type="pmid">11834590</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tishler</surname><given-names>DM</given-names></name><name><surname>Weinberg</surname><given-names>KI</given-names></name><name><surname>Hinton</surname><given-names>DR</given-names></name><name><surname>Barbaro</surname><given-names>N</given-names></name><name><surname>Annett</surname><given-names>GM</given-names></name><name><surname>Raffel</surname><given-names>C</given-names></name></person-group><article-title>MDR1 gene expression in brain of patients with medically intractable epilepsy</article-title><source>Epilepsia.</source><year>1995</year><volume>36</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1157.1995.tb01657.x</pub-id><?supplied-pmid 8001500?><pub-id pub-id-type="pmid">8001500</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>A</given-names></name><name><surname>Kerb</surname><given-names>R</given-names></name><name><surname>Weale</surname><given-names>ME</given-names></name><name><surname>Brinkmann</surname><given-names>U</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Goldstein</surname><given-names>DB</given-names></name><etal/></person-group><article-title>Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1</article-title><source>N Engl J Med.</source><year>2003</year><volume>348</volume><fpage>1442</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa021986</pub-id><?supplied-pmid 12686700?><pub-id pub-id-type="pmid">12686700</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><mixed-citation publication-type="other">PharmGKB. Gene-specific information tables for CYP2C9. 2017. <ext-link ext-link-type="uri" xlink:href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</ext-link>. Accessed 10 Mar 2017.</mixed-citation></ref><ref id="CR140"><label>140.</label><mixed-citation publication-type="other">PharmGKB. Gene-specific information tables for CYP2C19. 2017. <ext-link ext-link-type="uri" xlink:href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</ext-link>. Accessed 10 Mar 2017.</mixed-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassogue</surname><given-names>Y</given-names></name><name><surname>Dehbi</surname><given-names>H</given-names></name><name><surname>Nassereddine</surname><given-names>S</given-names></name><name><surname>Quachouh</surname><given-names>M</given-names></name><name><surname>Nadifi</surname><given-names>S</given-names></name></person-group><article-title>Genotype variability and haplotype frequency of MDR1 (ABCB1) gene polymorphism in Morocco</article-title><source>DNA Cell Biol.</source><year>2013</year><volume>32</volume><fpage>582</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1089/dna.2013.2108</pub-id><?supplied-pmid 23930592?><pub-id pub-id-type="pmid">23930592</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bournissen</surname><given-names>FG</given-names></name><name><surname>Moretti</surname><given-names>ME</given-names></name><name><surname>Juurlink</surname><given-names>DN</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Finkelstein</surname><given-names>Y</given-names></name></person-group><article-title>Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: a meta-analysis</article-title><source>Epilepsia.</source><year>2009</year><volume>50</volume><fpage>898</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2008.01858.x</pub-id><?supplied-pmid 19178561?><pub-id pub-id-type="pmid">19178561</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CC</given-names></name><name><surname>Ng</surname><given-names>CC</given-names></name><name><surname>Too</surname><given-names>CL</given-names></name><name><surname>Choon</surname><given-names>SE</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Chung</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population</article-title><source>Pharmacogenom J.</source><year>2017</year><volume>17</volume><fpage>170</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1038/tpj.2016.10</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>YK</given-names></name><name><surname>Cheng</surname><given-names>SH</given-names></name><name><surname>Chan</surname><given-names>EJ</given-names></name><name><surname>Lo</surname><given-names>SV</given-names></name><name><surname>Ng</surname><given-names>MH</given-names></name><name><surname>Kwan</surname><given-names>P</given-names></name></person-group><article-title>HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese</article-title><source>Epilepsia.</source><year>2013</year><volume>54</volume><fpage>1307</fpage><lpage>1314</lpage><pub-id pub-id-type="doi">10.1111/epi.12217</pub-id><?supplied-pmid 23692434?><pub-id pub-id-type="pmid">23692434</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celeste</surname><given-names>BL</given-names></name><name><surname>Kwan</surname><given-names>P</given-names></name><name><surname>Baum</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>E</given-names></name><name><surname>Lau</surname><given-names>KM</given-names></name><name><surname>Cheng</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese</article-title><source>Epilepsia.</source><year>2007</year><volume>48</volume><fpage>1015</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2007.01022.x</pub-id><pub-id pub-id-type="pmid">17509004</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><collab>The PRISMA Group</collab></person-group><article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title><source>PLoS Med</source><year>2009</year><volume>6</volume><issue>7</issue><fpage>e1000097</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id><?supplied-pmid 19621072?><pub-id pub-id-type="pmid">19621072</pub-id></element-citation></ref></ref-list></back></article>